Ajuga Turkestanica as a Countermeasure Against Sarcopenia and Dynapenia by Lawrence, Marcus Michael & NC DOCKS at Appalachian State University
	  
    
 
 
 
 
AJUGA TURKESTANICA AS A COUNTERMEASURE AGAINST 
SARCOPENIA AND DYNAPENIA 
 
 
 
 
 
 
A Thesis 
by 
MARCUS MICHAEL LAWRENCE 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate School 
Appalachian State University 
in partial fulfillment of the requirements for the degree of 
MASTER OF SCIENCE 
 
 
 
 
 
 
 
 
August 2012 
Department of Health, Leisure and Exercise Science 
 
 
 
 
 
 
 
	  
AJUGA TURKESTANICA AS A COUNTERMEASURE AGAINST 
SARCOPENIA AND DYNAPENIA 
 
 
 
 
 
 
A Thesis 
by 
MARCUS MICHAEL LAWRENCE 
August 2012 
 
 
 
 
 
 
APPROVED BY: 
 
 
_________________________________  
Kevin A. Zwetsloot, Ph.D. 
Chairperson, Thesis Committee 
 
 
_________________________________  
R. Andrew Shanely, Ph.D. 
Member, Thesis Committee 
 
 
_________________________________  
Susan Tsivitse Arthur, Ph.D. 
Member, Thesis Committee 
 
 
_________________________________  
Paul L. Gaskill, Ed.D. 
Chairperson, Department of Health, Leisure and Exercise Science 
 
 
_________________________________  
Edelma D. Huntley, Ph.D. 
Dean, Research and Graduate Studies 
 
 
	  
 
 
 
 
 
Copyright by Marcus Michael Lawrence 2012 
All Rights Reserved 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
	  
 
 
 
 
 
FOREWORD 
 
The research detailed in this thesis will be submitted as a research article to Muscle & 
Nerve, an internationally peer-reviewed journal owned by the American Association of 
Neuromuscular and Electrodiagnostic Medicine and published by John Wiley & Sons.  The 
thesis has been prepared according to the guidelines set forth by the Graduate School of 
Appalachian State University. 
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ABSTRACT 
 
AJUGA TURKESTANICA AS A COUNTERMEASURE AGAINST  
SARCOPENIA AND DYNAPENIA. (August 2012) 
 
Marcus Michael Lawrence, B.S., California State University Monterey Bay 
 
M.S., Appalachian State University 
 
Chairperson: Kevin A. Zwetsloot 
 
Protein synthesis signaling through the PI3k-Akt pathway and mitochondrial 
biogenesis signaling through the AMPK and p38-MAPK pathways are reduced in aged 
skeletal muscle, leading to the loss of muscle mass and strength.  Phytoecdysteroids, in 
particular 20-hydroxyecdysone (20E), from the plant Ajuga turkestanica increases protein 
synthesis in C2C12 skeletal muscle cells and muscle strength in young rats.  The objective of 
this study was to determine if an extract from A. turkestanica (ATE), enriched in 
phytoecdysteroids, affects muscle fiber size, weight, and strength and PI3k-Akt, AMPK, and 
p38-MAPK signaling in skeletal muscle of aged mice.  Aged male C57BL/6 mice (20-
months) received ATE, 20E, or control (CT; vehicle only of 100% non-denatured ethanol) 
for 28 days.  No significant differences (NSD) were observed between treatments in body, 
muscle, or organ mass, as well as during the in vivo contractile function (i.e., strength and 
endurance) of the gastrocnemius-plantaris-soleus complex.  Hemotoxylin and eosin staining 
revealed 41% and 30% larger fiber cross-sectional area (CSA) in the triceps brachii (p = 
0.014) and plantaris (p = 0.018) muscles of 20E-treated sedentary mice, respectively, 
compared to CT.  ATE treatment resulted in larger, but NSD in CSA of the triceps brachii 
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(26%; p = 0.088) and plantaris (8%; p = 0.497) muscles, compared to CT.  Western blotting 
performed on gastrocnemius muscles demonstrated NSD between treatments in non-
contracted and contracted phosphorylation of protein synthesis signaling markers (i.e., 
AktSer473 and p70S6kThr389).  NSD were observed between treatments in non-contracted 
phosphorylation of upstream mitochondrial biogenesis signaling markers (i.e., p38-
MAPKThr180/Tyr182 and AMPKThr172) and contraction-induced phosphorylation of p38-
MAPKThr180/Tyr182.  Additionally, contraction-induced phosphorylation of AMPKThr172 was 
significantly greater in 20E-treated mice when compared to CT and ATE, respectively.  In 
conclusion, these data suggest that 20E rescues the loss of muscle fiber size and increases 
activation of contraction-induced AMPK pathway signaling in sedentary aged skeletal 
muscle.  
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
INTRODUCTION 
 
 With the growing number of “baby-boomers” (those born between 1946 and 1960) 
getting older in the United States of America (USA), there is an ever increasing number of 
older adults living longer.  Although this speaks positively for modern-day health care, a 
large percentage of this population is unable to perform independent activities of daily living 
(ADLs).1  The inability to perform ADLs independently increases the burden on the 
country’s health care system to care for these individuals.  The large majority (1 in 5) of this 
population suffers from chronic conditions, such as sarcopenia and dynapenia,2 both of which 
can contribute to reductions in ADL.   
The term sarcopenia (from the Greek words sarx [flesh] and penia [loss], translating 
to the “poverty of flesh”)3 is defined as the age-associated loss of skeletal muscle mass.3  The 
term dynapenia (from the Greek words dynami [strength] and penia [loss], translating to the 
“poverty of strength”)4 is defined as the age-associated loss of skeletal muscle strength.4  
These two chronic conditions often arise from or lead to a decrease in physical activity which 
leads to an increased susceptibility to other chronic disorders such as insulin resistance, type 
2 diabetes, cardiovascular disease, and even death.5  With the loss of muscle mass and 
strength with age, there is typically a reduction in physical activity which then accelerates the 
loss of muscle mass and strength and creates a vicious cycle that continuously builds on one 
another and can eventually lead to death.5  Therefore, there is a critical need to understand 
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the mechanisms of sarcopenia and dynapenia in order to create viable countermeasures that 
can attenuate the negative outcomes associated with the two conditions.  
 Older adults have been found to have a blunted ability to promote muscle protein 
synthesis (MPS) as well as mitochondrial biogenesis.6-9  Both of these factors have been 
found to have a large effect on the age-associated loss of muscle mass and strength.  Blunted 
MPS in older adults is due, in large part, to reductions in signaling pathways that regulate 
MPS, amino acid and protein intake, hormone levels, and physical activity.8,9  Whereas, 
blunted mitochondrial biogenesis in older adults is due, in large part, to reductions in 
signaling pathways directly involved in mitochondrial biogenesis, upregulation of reactive 
oxygen and nitrogen species (RONS), as well as reductions in antioxidant enzyme content 
and activity.6,7  Further research is needed to devise optimal countermeasures for improving 
MPS and mitochondrial biogenesis with aging.  
 Ajuga turkestanica is a plant known to have adaptogenic properties (i.e., enhances 
mental and physical performance capabilities by promoting vitality and increasing the 
organism’s resistance to stress and aging).10  A. turkestanica contains bioactive components 
that have the potential for being a countermeasure against sarcopenia and dynapenia.  One 
possible mechanism of investigation for A. turkestanica as a countermeasure against 
sarcopenia and dynapenia is through measuring the effects of A. turkestanica on MPS and 
mitochondrial biogenesis signaling with aging.  In summary, sarcopenia and dynapenia are 
two chronic conditions that affect the global economy and are caused, in part, by reductions 
in MPS and mitochondrial biogenesis signaling.  A. turkestanica presents itself as a proposed 
countermeasure against sarcopenia and dynapenia and will be examined in that capacity by 
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determining A. turkestanica’s effects on MPS and mitochondrial biogenesis signaling with 
aging.  
 The goal of this literature review is to provide background information on sarcopenia 
and dynapenia, to examine the role of MPS and mitochondrial biogenesis signaling in 
sarcopenia and dynapenia, and to review current countermeasures used to prevent or reverse 
the effects of sarcopenia and dynapenia.  Finally, A. turkestanica will be reviewed as a 
proposed countermeasure against sarcopenia and dynapenia.    
LITERATURE REVIEW 
 Sarcopenia and Aging.  Estimates of the prevalence of sarcopenia in the USA range 
from 13% to 24% in adults over 60 years of age to more than 50% in persons aged 80 and 
older.11  The estimated direct healthcare costs attributable to sarcopenia in the USA in 2000 
were $18.5 billion ($10.5 billion in men, $7.7 billion in women), which represented about 
1.5% of total healthcare expenditures for that year.12  From the age of 20 to 80 years old, 
there is approximately a 40% reduction in muscle mass and a 20% decline in muscle cross-
sectional area.13  These losses can be attributed to a loss in both muscle fiber size and 
number.14  The most commonly used method for determining sarcopenia in an individual is 
by establishing a skeletal muscle mass index obtained by dividing appendicular skeletal 
muscle mass (ASM), evaluated by dual-energy X-ray absorptiometry (DEXA), by body 
height squared (i.e., ASM/ht2).15  Older adults presenting a skeletal muscle mass index of 1-2 
standard deviations below the mean of young control adults have class I sarcopenia 
(moderate); whereas, older adults with a skeletal muscle mass index of 2 or more standard 
deviations below the mean of young control adults have class II sarcopenia (severe).15  
Sarcopenia affects 100% of the population, as everyone loses muscle mass over time.  
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However, the rate of decline in muscle mass is determined by the individual, as some 
individuals lose muscle mass faster than others.16   
Sarcopenia is a multifactorial process associated with genetic heritability,17 protein 
intake,17 energy intake,17 apoptosis,17 hormonal changes,17 insulin resistance,17 changes in 
proinflammatory cytokines,17 decreases in mitochondrial density,18 function and volume,18 
and increases in RONS production.18  Sarcopenia typically correlates to a decrease in 
physical activity and a concomitant increase in physical frailty and even death.19  
Baumgartner et al.20 demonstrated that the likelihood of having a physical disability was 4 
times greater in sarcopenic older men and women than in older persons with a normal muscle 
mass.   
Dynapenia and Aging.  Dynapenia is a term coined4 to dissociate the loss of both 
muscle mass (i.e., sarcopenia) from the loss of muscle strength (i.e., maximal voluntary force 
output) alone.  Since the original definition of sarcopenia was introduced in 1989 by Dr. 
Irwin Rosenburg3 (i.e., the age-associated loss of muscle mass and size) there has been an 
exponential increase in research pertaining to the mechanisms involved in the age-associated 
loss of muscle mass.  In the past decade, the definition of sarcopenia has grown to include the 
age-associated loss of muscle mass as well as strength.  Early epidemiological data on 
sarcopenic older adults linked the loss of muscle mass with the loss of muscle strength21.  
However, recent research is demonstrating that this may not be the case.4,22-25  There is a 
definite overlap between the two conditions, therefore both conditions need to be examined 
together and not just solely examined independently. 
Dynapenia is a multifactorial process that can be largely attributed to reductions in 
the neuromuscular system as well as reductions within the skeletal muscle system (i.e., 
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sarcopenia).  However, the latter system seems to play a smaller role in dynapenia than 
previously thought.4  There is currently no universal method for determining dynapenia, but 
the most recent method utilized determining muscle strength (kg) via dynamometer and 
dividing that value by appendicular skeletal muscle mass (kg) as determined by DEXA.22  
The same authors also defined type I dynapenia, the only type of dynapenia accepted 
throughout the literature, as muscle strength (via hand dynamometer) as less than 1.53 kg per 
kg skeletal muscle mass.22  Unfortunately, there is not a definitive method for determining 
dynapenia, therefore, there is lack of epidemiological data to determine the prevalence of this 
condition.26 
The neuromuscular system, as opposed to the skeletal muscle system, is the greatest 
contributor to strength output, and this can be seen during the initial phase of adaptation to 
resistance training (RT).  The initial increases in maximal voluntary force (i.e., strength) 
observed during the early adaptation period of RT (the first 2 to 6 weeks) are evident, 
independent of an increase in muscle mass, suggesting an increase in the synchronization and 
recruitment of neuromuscular factors.27,28  Stevens et al.29 compared the neuromuscular 
system’s ability to fully activate knee extensor muscles (i.e., maximal voluntary force) 
compared to maximal electrical stimulation of the same muscles in 46 younger and 46 older 
adults to determine if there was a difference in “added force” with the electrical stimulation 
above what the subjects were able to recruit voluntarily.  The authors reported that there was 
an 11% reduction in central nervous system activation in older adults when compared to 
young controls indicating that older adults have a reduced ability to voluntarily activate 
muscle strength.29  Changes in the neuromuscular system with aging can be characterized by 
a loss of motor neurons (due to apoptosis), a decrease in motor unit number (a motor unit is 
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an α-motor neuron and all the muscle fibers that it innervates), and fiber type transformation 
(i.e., a selective loss of fast-twitch fibers with a concomitant increase in slower “hybrid” 
fibers).30  All of these factors contribute to dynapenia to a greater extent than just the loss of 
muscle mass alone. 
The original longitudinal studies21 used skeletal muscle cross-sections and strength 
output to track the changes between the two measurements and to determine if there was a 
link between the two.  The original data suggest that there was a link between the loss of 
muscle mass and strength,21; however, recent research is reporting that this may not be the 
case.4,22-25  For example, Goodpaster et al.23 measured appendicular skeletal muscle lean 
mass (via DEXA and computer tomography) and knee extensor strength (via isokinetic 
dynamometry) three years after an initial baseline measurement of the same variables in a 
group of 1880 older adults (age 70-79 years) and reported that the loss of lean mass was 
associated with the loss of strength; however, the rate of loss of strength was three times 
greater than the rate of loss of lean mass.  The authors also demonstrated that a gain in lean 
mass was not accompanied by concomitant increases or maintenance of strength.23  In other 
words, greater precedence should be placed on the loss of muscle strength, than just the loss 
of muscle mass.  Visser et al.25 demonstrated in the Health, Aging, and Body Composition 
study of 70-79 year old adults that the loss in muscle mass was associated with physical 
function decline; however, the degree of reduction in those variables (i.e., muscle mass and 
physical function) were both reliant on the level of strength of the individual; indicating that 
strength level was the key factor leading to reductions in muscle mass and physical function. 
To further dissociate sarcopenia and dynapenia, Newman et al.24 demonstrated that older 
adults with dynapenia had a 50% increase in all-cause mortality risk independent of 
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sarcopenia, but that older adults with sarcopenia did not have a significant increased all-cause 
mortality risk independent of dynapenia.  
Sarcopenic factors, beyond just the loss of muscle mass, also play a role in reducing 
maximal voluntary force.  These factors include changes in skeletal muscle architecture (i.e., 
infiltration of intramuscular lipids making the muscle intrinsically weak, and increases in 
rigidity of muscle proteins), fiber type transformations, and a reduction in excitation-
contraction coupling (i.e., the process of muscle contractions from an action potential in the 
central nervous system to the actual contraction of the muscle myofilaments).18  This age-
related decline in both the neuromuscular and skeletal muscle systems leads to impairments 
in maximal muscle strength, power, and rate of force development that translates into a 
reduction in physical function.30  The loss of strength and power is greater in the lower body 
than upper body and this is directly attributable to a decline in ADLs.31  Since the two 
chronic conditions (i.e., sarcopenia and dynapenia) can overlap and, in most cases, influence 
one another (although dynapenia may have a greater influence than sarcopenia), 
understanding the mechanisms by which the two chronic conditions act upon each other is of 
great relevance to overcome the burden that these two conditions place on our society. 
Regulation of Skeletal Muscle Mass and Aging.  It has been hypothesized that a 
contributing factor to the age-associated loss of skeletal muscle mass and strength is due to 
impairments in skeletal muscle protein homeostasis (i.e., the balance between MPS and 
muscle protein breakdown; MPB).32  The ability to maintain skeletal muscle protein 
homeostasis and, thus, overall lean mass relies on the pathways involved in both MPS and 
MPB to function properly.  With age there appears to be reductions in MPS pathways and 
upregulation of MPB pathways leading to the loss of skeletal muscle mass and strength.33  
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The major pathways involved in MPS and MPB that are associated with sarcopenia and 
dynapenia will be briefly reviewed including the interaction between the two pathways that 
contribute in large part to sarcopenia and dynapenia.  
 PI3k-Akt Pathway and Aging.  The largest contributor to the loss of muscle mass 
(and in small part the loss of muscle strength) due to aging is a blunted response to promote 
MPS.  MPS is controlled in large part by the phosphoinositide 3-kinase (PI3k)-Akt (or 
protein kinase B)-mammalian target of rapamycin (mTOR; or PI3k-Akt-mTOR) pathway.34  
MPS through the PI3k-Akt-mTOR pathway can be stimulated via growth factors (i.e., insulin 
and insulin-like growth factor 1; IGF-1), nutrition (i.e., amino acids), and mechanical stimuli 
(i.e., resistance training; RT).  The PI3k-Akt-mTOR pathway can also be activated by second 
messenger signaling via the Ca2+-dependent G-protein coupled-receptor pathway (discussed 
below).35 
PI3k causes increases in phosphatidylinositol 3,4,5-triphosphate (PIP3), leading to 
recruitment of Akt from the cytosol to the sarcolemma and phosphorylation of Akt.36  Akt 
activation is a crucial step involved in MPS37 as well as reduction in MPB (discussed 
below).34  Activated Akt phosphorylates tuberous sclerosis protein 1/hamartin (TSC1) and 
tuberous sclerosis protein 2/tuberin (TSC2), or the TSC1/TSC2 complex that releases their 
inhibition on mTOR activation.38  Thus, Akt’s phosphorylation of the TSC1/TSC2 complex 
allows mTOR to induce its effects on MPS.  Akt also phosphorylates glycogen synthase 
kinase-3β (GSK-3β), leading to its inhibition and, thus, upregulation of protein synthesis.39  
GSK-3β inhibits eukaryotic translation initiation factor 2E (eIF-2E) which is involved in 
protein translation.  Thus, inhibition of GSK-3β leads to increased MPS.40  Additional details 
of this pathway are beyond the scope of this review. 
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mTOR is a highly conserved serine-threonine kinase that is a key regulatory protein 
for processes such as cell proliferation, cell growth, energy homeostasis, substrate 
metabolism, and protein synthesis.41  The mTOR signaling cascade is a key control point for 
MPS and, thus, muscle growth (i.e., hypertrophy).34  Administration of the pharmaceutical 
mTOR inhibitor rapamycin has been shown to completely block MPS in response to 
resistance training (i.e., anabolic stimuli).42  
mTOR exists in two structurally and functionally different complexes that include 
mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).41  mTORC1 is a critical 
control point in MPS;34 whereas, mTORC2 is a regulator of insulin-stimulated glucose 
uptake in skeletal muscle.43  mTOR’s effects on MPS are directly linked to the 
phosphorylation of its downstream targets 70-kilodaltin ribosomal S6 protein kinase 
(p70S6k) and eukaryotic translation initiation factor 4E-binding protein (4E-BP1; also known 
as PHAS-1).44  mTORC1 phosphorylates 4E-BP1, thereby enhancing translation.  Typically, 
4E-BP1 inhibits translation when it is bound to the eukaryotic translation initiation factor-4E 
(eIF-4E) and, thus, mTORC1 releases 4E-BP1 from its binding site allowing translation to 
occur.45  p70S6k is a crucial regulator of initiation of mRNA translational machinery of 
protein synthesis.46  Furthermore, in insulin stimulated skeletal muscle cells, p70S6k 
activation is inhibited by expression of the TSC1/TSC2 complex.38  The inhibition of p70S6k 
by the TSC1/TSC2 complex expression indicates that Akt must phosphorylate and, thereby, 
release the TSC1/TSC2 complex’s inhibition of mTOR in order for mTOR to phosphorylate 
p70S6k and initiate MPS translation.  Thus, the PI3k-Akt-mTOR-p70S6k (PI3k-Akt) 
pathway is a crucial regulator of MPS.   
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Since the ability to gain or even maintain lean muscle mass (and strength, to a certain 
extent) is critically regulated by the PI3k-Akt pathway, it is necessary to understand how that 
pathway is affected by aging.  There are conflicting findings in regards to resting MPS in 
older adults, as some studies have shown no differences in resting MPS47,48 when compared 
to young healthy controls, whereas others have demonstrated a decrease in resting MPS.49,50  
Therefore, there is no consensus on the effects of resting MPS on aging.  However, in 
response to anabolic stimuli (i.e., RT) there is a clear blunting of MPS with aging.8 
No differences have been found between resting PI3k-Akt signaling in older adults 
when compared to untrained young controls.51-53  However, in response to anabolic stimuli 
(i.e., RT) Fry et al.8 demonstrated that aged individuals were found to have a reduction in not 
only the phosphorylation of specific targets (i.e., mTOR, p70S6k, and 4E-BP1) within the 
PI3k-Akt pathway, but also in MPS (as measured by the amount of L-[ring-
13C6]phenylalanine incorporated into muscle biopsy samples) when compared to young 
controls.  Fujita et al.52 administered supraphysiological and physiological (i.e., insulin 
infusion) doses to older adults postprandial (i.e., post-meal) and reported a reduction in the 
phosphorylation of Akt and p70S6k in the physiological dose experiment.  This indicates that 
there is not only an age-related insulin resistance, but also that there are reductions within the 
PI3k-Akt pathway in response to anabolic stimuli.52  Other studies have also reported a 
reduced efficiency or blunting of phosphorylation within the PI3k-Akt pathway leading to 
reduced ability to promote MPS.54-56  Therefore, the loss of muscle mass and strength with 
aging may be due, in part, to a blunted response to proper activation of the PI3k-Akt 
pathway.   
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Muscle Protein Breakdown, PI3k-Akt, and Aging.  Since the age-associated loss of 
muscle mass and strength is not only reliant on MPS, but also MPB, it is important to 
examine the interaction between the MPS and MPB pathways.  The loss of muscle mass is 
determined by the net balance between MPS and MPB.  There are at least four major 
pathways involved in MPB including lysosomal proteases (i.e., cathepsins), the Ca2+-
dependent calpain system, the caspase-dependent system and the ubiquitin-proteosome 
pathway (for review see33,57).  While all four of these pathways are significantly affected by 
aging57 only the most predominant pathway, the ubiquitin-proteasome pathway that has cross 
talk with the PI3k-Akt pathway, will be reviewed. 
The ubiquitin-proteasome pathway works by tagging a protein for degradation with 
attachment of single protein pieces or chains of the protein called ubiquitin and then 
transporting the ubiquitinated protein to the proteasome for degradation.  Ubiquitin is added 
to proteins targeted for degradation in the proteasome by a process involving at least three 
classes of proteins called E1 (ubiquitin activating), E2 (ubiquitin conjugating), and E3 
(ubiquitin ligating) enzymes.33  Two E3 ligases have been clearly linked to muscle atrophy in 
skeletal muscle, Muscle Ring Finger 1 (MuRF1), and Muscle Atrophy F-box (MAFbx).58  
MuRF1 and MAFbx are activated by the forkhead box (FOXO) family of transcription 
factors as well as the nuclear factor kappa B (NF-κB) pathway (discussed below).59,60  Both 
MuRF1 and MAFbx are upregulated in almost all cases of muscle atrophy, which appears to 
be the result of an increase in the amount of FOXO family of transcription factors 
activation.60  Bodine et al.58 demonstrated that knocking out either MuRF1 or MAFbx spared 
the loss of muscle mass, indicating that both E3 ligases are crucial for MPB.  
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There is cross talk between the PI3k-Akt pathway and the ubiquitin-proteasome 
pathway.61,62  Akt not only indirectly activates mTOR, but it also has been shown to play a 
role in downregulating MPB by phosphorylating and, thus, inhibiting the activation of the 
FOXO family of transcription factors.62  Stitt et al.62 found that overexpression of Akt in 
skeletal muscle myotubes inhibited both the FOXO family of transcription factors activation 
and also decreased the expression of the E3 ligase MAFbx.  This study indicates the 
importance of the PI3k-Akt pathway’s, specifically Akt, inhibition of MPB by 
phosphorylation of the FOXO family of transcription factors.  One current theory of 
increased MPB with aging is that with reduced physical activity (i.e., mechanical stimuli) 
there is reduced phosphorylation of the FOXO family of transcription factors by Akt leading 
to upregulation of MuRF1 and MAFbx and thus MPB.33  Therefore, proper activation (i.e., 
the normal activation observed in healthy young adults) of the PI3k-Akt pathway is essential 
for preventing and even reducing the age-associated loss of muscle mass and strength. 
Sarcopenia and dynapenia are not only associated with a depressed rate of MPS in 
response to anabolic stimuli,8 but have also been linked to a chronic increase in pro-
inflammatory cytokines, specifically interleukin-6 (IL-6) and tumor necrosis factor α 
(TNFα).63  Visser et al.64 demonstrated in the Health, Aging, and Body Composition study of 
3075 older adults between 70-79 years old, that individuals with the highest levels of 
circulating pro-inflammatory cytokines, specifically IL-6 and TNFα, had the lowest levels of 
muscle mass and strength.  IL-6 has been linked to the age-associated loss of muscle mass 
and strength.64  However, the effects of IL-6 on skeletal muscle has produced conflicting 
results.64-66  IL-6 has been shown to be both a pro- and anti-inflammatory cytokine, with the 
differing biological effects believed to be due to the site (i.e., adipose and muscle tissue, 
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respectively) of IL-6 secretion.64,66-69  Thus, there is currently no consensus on IL-6’s effects 
on sarcopenia and dynapenia.   
TNFα has also been linked to the age-associated loss of muscle mass and strength.64  
TNFα has been found to induce RONS production as well as upregulation of MPB via the 
ubiquitin proteasome pathway.59,70-72  The TNFα induced RONS production leads to 
activation of nuclear factor kappa B (NF-κB) via degradation of inhibitory kappa B (I-κB) in 
the proteasome.73  NF-κB is a transcription factor that regulates cytokine and cytokine 
receptor gene expression, and is regulated by attachment of I-κB.  Hence, when I-κB is 
degraded in the proteasome via TNFα induced RONS production, NF-κB is then allowed to 
induce its effects on skeletal muscle.  NF-κB activation via TNFα induced RONS production 
has been found to increase MuRF1 and MAFbx expression leading to MPB.59,72  Therefore, a 
countermeasure that can both activate MPS (by activating the PI3k-Akt pathway) and reduce 
MPB (by down regulating the ubiquitin-proteasome pathway) is essential in counteracting 
the age-associated loss of skeletal muscle mass and strength. 
Regulation of Mitochondrial Biogenesis and Aging.  Mitochondrial homeostasis 
(i.e., the balance of protein turnover during repair or recycling of mitochondrial proteins 
through protein synthesis and protein degradation) consists of maintaining mitochondrial 
biogenesis.  Mitochondrial biogenesis is defined as the process by which new mitochondrion 
are formed in the cell.  The proteins that form new mitochondrion or repair damaged 
mitochondrion are produced from the transcription and translation of genes both in the 
nuclear genome and in the mitochondrial genome.74  With cellular aging, there is a loss of 
mitochondrial homeostasis and increased dysfunction. 
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The mitochondrial theory of aging was proposed in 1956 and states that, with aging, 
there is increased RONS production from mitochondria that results in mutations of 
mitochondrial DNA (mtDNA), a reduced efficiency to produce adenosine tri-phosphate 
(ATP), and ultimately cellular dysfunction.75  The age-associated loss of muscle mass and 
strength has, in part, been linked to an increase in RONS production leading to mitochondrial 
dysfunction76 and a reduced ability to stimulate mitochondrial biogenesis.7  RONS refers to 
both free radical (i.e., one or more unpaired electron in an atom or molecule) and non-free 
radical species (where the reactive center is either nitrogen or oxygen).77  The primary free 
radicals generated in cells are superoxide (O2-) and nitric oxide (NO), and both molecules can 
readily react to form a series of other RONS.77  RONS production increases with age due to 
altered electron transport chain function (i.e., the greatest producer of cellular high energy 
phosphates; ATP) and decreases in antioxidant enzyme (i.e., superoxide dismutase, 
glutathione peroxidase, and catalase) content and function.  The increases in RONS 
production and decreases in antioxidant enzyme content and activity leads to damage of 
mtDNA and can subsequently lead to an accumulation of cell loss through apoptosis such as 
in sarcopenia and dynapenia.7,76-77  Therefore, the pathways involved in maintaining 
mitochondrial homeostasis through promoting mitochondrial biogenesis will be reviewed in 
the context of their contribution to sarcopenia and dynapenia. 
AMPK, p38-MAPK, and Mitochondrial Biogenesis.  At the molecular level, there 
are several transcription factors and cofactors that are involved with the activation and 
regulation of mitochondrial biogenesis.78  However, the major control point or “master 
regulator”79 of mitochondrial transcription (and, thus, mitochondrial biogenesis) has been 
found to be peroxisome proliferators-activated receptor co-activator 1 (PGC-1α).79  PGC-1α 
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has been suggested to provide control of cellular ATP homeostasis via regulation of 
mitochondrial biogenesis.80  Cui et al.81 demonstrated PGC-1α’s physiological importance by 
reporting that repression of PGC-1α by a mutant form of the Huntington protein (i.e., 
Huntington’s disease) leads to mitochondrial dysfunction (and, thus, reduced mitochondrial 
biogenesis) and neurodegeneration.  The same authors also demonstrated that overexpression 
of PGC-1α rescues cells from the negative effects of the Huntington protein.81  Also, with 
aging there is reduced expression of PGC-1α,82 and its absence is believed to promote the 
accumulation of damaged mitochondria,79 which is thought to be the basis of increased 
mitochondria dysfunction79 and, thus, increases in sarcopenia and dynapenia.  PGC-1α can be 
activated by numerous factors including silent informational regulator ortholog of 
mammalian sirtuin (SIRT1), the acetylase transferase (GCN5), nitric oxide (NO), 5’ AMP-
activated protein kinase (AMPK), and p38- mitogen-activated protein kinase (p38-
MAPK),78,83 however, only the AMPK and p38-MAPK pathways will be reviewed. 
    During endurance training (ET; i.e., low-intensity exercise with a relatively high 
number of contractions) the high demand and breakdown of ATP generates high levels of 
adenosine monophosphate (AMP).  When AMP to ATP (AMP:ATP) ratios are high in the 
cell (indicating a low cellular energy level), AMPK is activated in skeletal muscle.84  AMPK 
directly phosphorylates PGC-1α84 and induces post-translational modifications that make 
PGC-1α more stable and, thus, active.85  In addition, Canto et al.86 demonstrated that ET 
induced PGC-1α post-translational modifications and activation was blunted in AMPK-
knockout mice, indicating AMPK activation is a crucial regulator of PGC-1α activation and 
mitochondrial biogenesis initiation.87  With the increased AMP:ATP ratio (i.e., low-energy 
level), AMPK will not only increase the activation of energy producing mechanisms (i.e., 
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post-translational modifications of PGC-1α and activation of mitochondrial biogenesis), but 
there has also been strong evidence indicating that AMPK has cross-talk with the PI3k-Akt 
pathway.88  When cellular AMP:ATP ratio is high and AMPK is activated, AMPK will 
inhibit large energy-consuming pathways involved in anabolic processes such as the PI3k-
Akt pathway.  AMPK will activate the TSC1/TSC2 complex and, thereby, inhibit mTOR88 as 
well as decrease phosphorylation of p70S6k and 4E-BP1,89 thereby inhibiting MPS.  In 
aging, AMPK’s ability to “sense” the reduced cellular energy level is not only diminished,90 
but total AMPK content and activity are both decreased as well,91 thereby leading to a 
decreased activation of PGC-1α and thus mitochondrial biogenesis.   
In addition, ET activates stress-activated protein kinases, in particular p38-MAPK.87  
p38-MAPK directly phosphorylates and activates PGC-1α92 as well as transcription factors 
that directly bind to the PGC-1α promoter.87  Administration of the p38-MAPK inhibitor SB-
202190 to skeletal muscle cells prevented mitochondrial biogenesis,93 indicating that p38-
MAPK is a crucial regulator of mitochondrial biogenesis.  In addition, Pogozelski et al.94 
reported that the p38γ-MAPK isoform, and not the p38α-MAPK or p38β-MAPK isoforms, 
was required to induce mitochondrial biogenesis in skeletal muscle in response to ET in 
mice.  p38-MAPK content and activity decrease with aging, leading to decreased PGC-1α 
expression and, thus, mitochondrial biogenesis.6  Taken collectively, mechanisms that can 
activate the AMPK and p38-MAPK pathways to stimulate PGC-1α expression and activation 
and stimulate mitochondrial biogenesis could be a potent stimuli to help reduce or even 
prevent the age-associated loss of skeletal muscle mass and strength. 
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Countermeasures against Sarcopenia and Dynapenia.  Several countermeasures 
have been studied to establish feasible and safe interventions to improve muscle mass and 
strength.  Such interventions include RT, increasing food or energy intake, increasing protein 
or essential amino acid intake, and pharmaceuticals (i.e., hormone-replacement therapy).  All 
of these have the potential for increasing muscle mass and strength in older adults and will be 
further reviewed below.  Also, the effects of A. turkestanica on health and performance 
capabilities as well as the potential of A. turkestanica to be a viable countermeasure against 
sarcopenia and dynapenia will be reviewed. 
Resistance Training.  RT programs have proven to be one of the most effective 
interventions in counteracting the decreases in muscle mass and strength associated with age.  
The current recommendations from the American College of Sports Medicine for increasing 
muscle strength for older adults suggest that novices train 2 to 3 times per week with loads 
corresponding to 8 to 12 repetitions, while, for more experienced lifters, heavier load 
protocols and up to 4 to 5 training sessions per week are suggested.95  Numerous studies have 
shown improvements in both muscle mass and strength utilizing RT in older adults.96-99     
Traditionally, RT programs for older adults have been geared towards developing 
overall strength in the individuals.  However, Latham and colleagues compiled a systematic 
review on RT in older adults and suggest that increasing muscle strength does not necessarily 
translate into improvements in ADLs.100  Several other studies have reported that muscle 
power is more strongly correlated to improvements in ADLs in older adults.1,2,101-105  Muscle 
strength reflects the ability of the muscle to produce force; whereas, muscle power is defined 
as the product of force times velocity, or the ability of the muscle to produce force quickly.  
Therefore, since sarcopenia and dynapenia can contribute, in large part, to reductions in 
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ADLs the emphasis should be placed on increasing overall power output and not just 
strength. 
However, high volume (i.e., high number of total repetitions, sets, load, and intensity) 
RT programs are not feasible for many aged people in terms of compliance and ability to 
perform the exercises (i.e., functional performance).  Several studies106,107 report that high 
volume RT programs in older adults impair any positive gains experienced in muscle mass 
and strength, particularly in women.  This may be due, in part, to the blunted anabolic 
response to RT programs that is seen in older adults when compared to healthy, young 
controls.8,108  Therefore, particular attention needs to be placed on designing RT programs for 
older adults that take into account appropriate volume, frequency and feasibility of the 
workouts.  Properly designed RT programs for older adults have demonstrated increases in 
muscle mass and strength, but to a lesser extent than healthy, young controls.8,108  In 
summary, when properly designed RT programs are utilized as a countermeasure in older 
adults, there is an increase in muscle mass and strength, but to a lesser extent than the gains 
experienced by healthy, young adults which may be due, in part, to reductions in MPS 
signaling.  
Energy Intake, Protein Intake, and Essential Amino Acids.  One of the strongest 
causes of the reduction in MPS and increases in physical frailty is nutritional status.  This 
includes energy intake (i.e., the amount of food and energy consumed), protein intake, and 
essential amino acid intake.  A reduction in energy intake can have drastic impacts on muscle 
mass and physical function.  This reduction can compromise mitochondrial energy 
metabolism and lead to muscle fatigue, weakness, and debility.109  If body weight decreases 
with a reduced energy intake, not only are fat stores lost, but almost always skeletal muscle 
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mass is also lost.  When older adults experience weight loss, the reduction in muscle mass is 
greater than the reduction in young adults with similar weight loss.110 The optimal body mass 
index (BMI) for older adults (i.e., individuals over the age of 51 years) is higher than 
younger adults and is estimated to be between 22 and 33 kg/m2.  To achieve this BMI range, 
an older adult needs to ingest 24-36 kilocalorie per kilogram (kcal/kg) body weight per day 
(the equivalent to 1440-2160 kcal/day in a 60kg person).109  Therefore, maintenance of 
energy intake is essential for reducing and slowing the progression of sarcopenia and 
dynapenia. 
Since MPS requires protein, increasing dietary protein intake can stimulate MPS.  
However, the amount and type of dietary protein intake is different for older adults than 
young adults.  The current recommended dietary allowance (RDA) for protein intake is 0.8 g 
protein per kg/day in healthy adults.  The mean requirement for older adults is estimated to 
be 0.89 g protein/kg/day111 and up to 1.3 g protein/kg/day during debilitating conditions such 
as hospitalization.112  Houston et al.113 demonstrated that the loss of appendicular lean mass 
in older adults can be attenuated when a higher amount of dietary protein is consumed over a 
three year time period.  
 The type of dietary protein also plays a large role in balancing MPS and MPB.  
Animal protein has been found to have a greater effect on promoting MPS and inhibiting 
MPB when compared to vegetable protein.114  Also, the ability to absorb protein is reduced 
with age and thus “faster” proteins (i.e., whey) are recommended over “slower” proteins (i.e., 
casein).  Fast versus slow proteins refers the rate at which amino acids (i.e., from the 
breakdown of the proteins) appear in the blood stream and the speed at which the protein is 
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absorbed in the small intestine.115  Whey protein, over casein protein, has been reported to 
increase MPS in healthy older adults.116 
Furthermore, with age there is a reduction in the ability to metabolize amino acids 
and, thus, a larger dietary intake of amino acids is suggested.  Essential amino acids (EAAs), 
over non-essential amino acids, have been found to be the primary stimulus for MPS in 
healthy older adults.117  EAAs, in particular the branched chain amino acid (BCAA) leucine, 
can directly stimulate MPS by activating mTOR.118  As mentioned above, mTOR turns on 
the translational machinery responsible for protein synthesis and, thus, regulates muscle 
mass.34  Further, several studies119,120 have reported that the combination of RT and protein 
or EAA supplementation has a greater effect on increases in MPS and strength in older adults 
than the gains made by the two independently. 
 Inadequate nutrition in itself may contribute to the development of sarcopenia and 
dynapenia.121,122  Also, this relationship can work in reverse, as the age-associated loss of 
muscle mass and strength can lead to inadequate nutrition and, thus, cause a vicious cycle 
that amplifies one another.109  Overall, the increase in energy intake and the increase in 
quality protein intake, specifically the EAA leucine, can help to counteract or even prevent 
the losses of muscle mass and strength.  Further research is needed on additional nutritional 
interventions to counteract sarcopenia and dynapenia. 
Hormone Supplementation (Androgens, Growth Hormone, and Insulin-Like 
Growth Factor 1).  Hormone supplementation as an intervention to counteract or prevent the 
age-related declines in muscle mass and strength has grown in popularity in recent years.  
Estrogen supplementation in women has been reported to have a small effect on increasing 
muscle mass,123 but can also cause an increase in oxidative cancers (i.e., breast cancer).124  
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The two most prevalently used and studied hormones against the loss of muscle mass and 
strength are testosterone and human growth hormone (HGH).   
 Testosterone is a crucial hormone involved in regulation of skeletal muscle mass and 
strength with age.125  Blood testosterone levels decline with age in males.126  This decline in 
testosterone is linked to a loss in muscle mass, strength, and physical function127 and a 
decreased rate of MPS.48  Testosterone supplementation can increase muscle mass and 
strength in hypogonadal older adults.128  However, the amount of testosterone hormone 
needed to produce increases in muscle mass and strength in older adults is above 
physiological levels,129 and can lead to serious side effects such as cardiovascular disease, 
prostate enlargement, and certain cancers.130 
 HGH regulates the growth of tissues throughout the body, in particular skeletal 
muscle.  HGH regulates skeletal muscle growth in part by activating IGF-1.  IGF-1 works 
through the PI3k-Akt pathway to directly influence MPS.40  HGH can also independently 
promote skeletal muscle cell growth through a separate signaling cascade131 that is beyond 
the scope of this review.  HGH supplementation in older adults to counteract sarcopenia and 
dynapenia has shown both positive132 and negative133 results.  HGH supplementation, like 
testosterone, can lead to adverse side effects. 
 IGF-1 supplementation has also had positive134 and negative135 results on MPS in 
aged human and rodent models.  The significant decline in plasma IGF-1 observed in aged 
adults is negatively correlated with the rate of MPS.48  Even with the ability to promote MPS, 
IGF-1 also activates a plethora of other signaling pathways, including pathways that lead to 
tumor growth and certain cancers.136  Thus, IGF-1 supplementation needs further 
examination of whether it can be an appropriate countermeasure against sarcopenia and 
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dynapenia.  The negative side effects associated with these treatments emphasize the need of 
finding non-toxic and non-hormonal treatments to help increase muscle mass and strength.  
The current body of literature pertaining to hormone supplementation as a countermeasure to 
reverse or reduce the age-associated loss of muscle mass and strength has produced 
conflicting results indicating that further research is needed to determine if these treatments 
are viable countermeasures against sarcopenia and dynapenia. 
Ajuga turkestanica and Human Health.  Ajuga turkestanica, a wild plant native to 
Uzbekistan and other regions in Central Asia, is a traditional folk remedy used to enhance 
muscular strength and physical endurance.  Leaves of A. turkestanica contain an array of 
bioactive phytochemicals, in particular phytoecdysteroids and iriodoids.  Phytoecdysteroids 
isolated from A. turkestanica include ajugalactone, ajugasterone B, cyasterone, cyasterone-
22-acetate, ecdysterone and most predominantly, 20-hydroxyecdysone (20E) and 
turkesterone.137  The phytoecdysteroids from A. turkestanica are reported to contain an 
abundance of biological, pharmacological, and medicinal properties such as anabolic, 
analgesic, anti-inflammatory, antihypertensive, antioxidant, antibacterial, increased skin 
hydration (aquaporin production), renoprotective, hepatoprotective, increased red blood cell 
production and regeneration, reversal of mitochondrial dysfunction, normalization of cell 
energetics and lipid metabolism, and increased insulin sensitivity in diabetic animals.137  
Furthermore, these compounds are considered to be adaptogens.  Adaptogens enhance mental 
and physical capabilities by promoting vitality and increasing the organism’s resistance to 
stress and aging.10  Iridoids isolated from A. turkestanica include harpagide and 8-O-
acetlyharpigide.138  These particular iridoids contain a plethora of biological, 
pharmacological, and medicinal properties such as antitumor, fungicidal, antimicrobial, 
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antioxidant, anti-inflammatory, cholegogic (promotes bile secretion), and 
hepatoprotective.10,137  There is evidence that the acute toxicity of the compounds in A. 
turkestanica to mammals is extremely low with relatively no side effects.137,139  
Recent research has demonstrated than an extract produced from A. turkestanica was 
able to stimulate protein synthesis by 120% in cultured C2C12 skeletal muscle myotubes.140  
Additionally, when the PI3k inhibitor LY294002 was administered to the cell cultures 
protein synthesis was completely abolished,140 suggesting that the extract from A. 
turkestanica works through the PI3k-Akt pathway to stimulate MPS.  Finally, the authors 
demonstrated that the same compounds elicited their affects in vivo, by reporting that young 
rats fed 20E for 28 days increased muscular grip strength by 18%.140  The same group 
administered 20E to C2C12 skeletal muscle cells and reported an increase in Akt 
phosphorylation in a dose-dependent manner.35  The authors also reported that 20E Akt 
activation may be working through a G-protein coupled-receptor (GPCR) – phospholipase C 
(PLC) – inositol 3-phosphate receptor (IP3R) – PI3k pathway via increases of Ca2+ influx into 
the skeletal muscle cells (for a review of PLC-IP3R in skeletal muscle see Rozengurt et 
al.141).  This study demonstrates that activation of the PI3k-Akt pathway by 20E may not be 
working through an IGF-1 dependent mechanism.35  
Toth et al.142 demonstrated that 20E administration to rats not only increased muscle 
mass (by increasing both fast and slow twitch muscle fiber size), but also increased the total 
number of fiber myonuclei, suggesting activation of regenerative mechanisms (i.e., satellite 
cells) involved in skeletal muscle.  Other investigators10,137,143 have demonstrated that the 
compounds in A. turkestanica promote similar anabolic effects as androgens (i.e., 
testosterone), but have not shown any of the adverse side effects such as atrophy of the testes 
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or enlargement of tissues other than just skeletal muscle (i.e., prostate gland and cardiac 
muscle) that are experienced with exogenous hormone supplementation.10,137  Furthermore, 
the compounds in A. turkestanica are non-androgenic and work through an androgen receptor 
independent pathway.35  A. turkestanica could be a potential non-toxic, non-hormonal 
intervention to counteract the age-associated loss of skeletal muscle mass and strength.  
Additionally, no studies to date have investigated the effects of phytoecdysteroid 
supplementation on improving skeletal muscle mass and strength in 20-month old animals.   
SUMMARY 
Sarcopenia and dynapenia affect a large proportion of our global population and 
cause severe financial burdens on our health care system.  Countermeasures to alleviate the 
physical losses associated with sarcopenia and dynapenia require further research.  A 
countermeasure is needed than can stimulate MPS (PI3k-Akt pathway) or mitochondrial 
biogenesis (AMPK and p38-MAPK pathways) in aged skeletal muscle without adverse side 
effects.   A. turkestanica presents itself as a potential intervention to both decrease and 
prevent the age-associated loss of skeletal muscle mass and strength in a non-toxic, non-
hormonal way.   
STATEMENT OF PROBLEM 
Neither the anti-sarcopenic nor anti-dynapenic effects of A. turkestanica or 20E on 
aged skeletal muscle are known.  Therefore, the purpose of this study is to determine the 
effects of either ATE, 20E, or control (CT; vehicle only of 100% non-denatured ethanol, 
EtOH) fed to 20-month old male mice for 28 days on the ability to (1) increase strength and 
muscle mass, (2) activate the key control point of protein synthesis, the PI3k-Akt pathway, 
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and (3) activate key upstream control points for mitochondrial biogenesis, the AMPK and 
p38-MAPK pathways. 
HYPOTHESIS 
I hypothesize that ATE will (1) increase strength and muscle mass, (2) activate the 
key control point of protein synthesis, the PI3k-Akt pathway, and (3) activate key upstream 
control points for mitochondrial biogenesis, the AMPK and p38-MAPK pathways in 20-
month old male mice. The efficacy of ATE will be tested against 20E and CT. 
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CHAPTER 2: EXPERIMENT 
 
The loss of muscle mass (sarcopenia) and strength (dynapenia) with advanced age are 
associated with decreased physical function.  The loss of physical function can accelerate the 
loss of muscle mass and strength and create a vicious cycle that continuously builds on one 
another and can eventually lead to loss of independence and premature death.5  Therefore, it 
is critical to study countermeasures that can attenuate the outcomes associated with 
sarcopenia and dynapenia in the elderly.  
 The ability to stimulate MPS and mitochondrial biogenesis are impaired with aging,7 
both of which contribute to the loss of muscle mass and strength with age.6,7,76,144  Blunted 
MPS in older adults is due, in large part, to reductions in signaling pathways directly 
involved in protein synthesis (specifically the PI3k/Akt/mTOR/p70S6k; PI3k-Akt pathway), 
amino acid and protein intake, hormone levels, and physical activity.8,9  Whereas, blunted 
mitochondrial biogenesis in older adults is due, in large part, to reductions in signaling 
pathways directly involved in mitochondrial biogenesis, upregulation of RONS, decreased 
heat shock protein expression, as well as reductions in antioxidant enzyme content and 
activity.7,76,91  Taken collectively, a countermeasure that can both activate MPS and 
mitochondrial biogenesis pathways would be very important for reducing or even reversing 
the effects of sarcopenia and dynapenia.  Current countermeasures for sarcopenia and 
dynapenia include RT, increasing food or energy intake, increasing protein or essential amino 
acid intake, and pharmaceuticals (i.e., hormone-replacement therapy); however, for multiple 
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reasons these interventions are not entirely effective at attenuating sarcopenia and dynapenia 
in the elderly.109,122  
Ajuga turkestanica, a wild plant native to Uzbekistan and other regions in Central 
Asia, is a traditional folk remedy used to enhance muscular strength and physical endurance.  
Leaves and shoots of A. turkestanica contain an array of bioactive phytochemicals, in 
particular phytoecdysteroids.  Phytoecdysteroids are plant-produced analogues of 
ecdysteroids, insect molting hormones that control cell proliferation, growth, and 
development.139  The structures of phytoecdysteroids vary according to the number, location, 
and position of hydroxyl substituents on a steroid backbone.10,145  The phytoecdysteroids 
from A. turkestanica are reported to have anabolic, analgesic, anti-inflammatory, 
antihypertensive, antioxidant, antibacterial, and hepatoprotective properties.10,137  Recent 
research has demonstrated that an extract, enriched in phytoecdysteroids, produced from A. 
turkestanica stimulates protein synthesis by 120% via the PI3k-Akt pathway in cultured 
C2C12 skeletal muscle myotubes.140  In addition, young rats fed 20E at 50 milligrams per 
kilogram per day (mg/kg/day) for 28 days increased muscular grip strength by 18%.140  
These data suggest that A. turkestanica may possess the properties to increase MPS and 
strength.  Furthermore, the acute toxicity of phytoecdysteroids is very low to mice: the LD50 
of 20E is >9 grams per kilogram (g/kg) body weight when given orally and 6.4 g/kg body 
weight if injected intraperitoneally.146,147  It is unknown if A. turkestanica works to combat 
sarcopenia and dynapenia in aged skeletal muscle.  Therefore, the purpose of the current 
study was to determine the effects of ATE, 20E, or vehicle only (CT) fed to 20-month old 
male mice for 28 days on their ability to (1) increase strength and muscle mass, (2) activate 
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the key control point of protein synthesis, the PI3k-Akt pathway, and (3) activate key 
upstream control points for mitochondrial biogenesis, the AMPK and p38-MAPK pathways. 
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MATERIALS AND METHODS 
Plant Materials and Crude Extraction.  Whole A. turkestanica plant material was 
harvested in Las Palmas, Spain (PoliNat; Las Palmas, Spain) in April-June 2008.  The plant 
material was air dried and milled to 1-2 mm particle size. A crude extraction consisting of a 
30:70 water-ethanol solvent solution at 60°C to extract phytoecdysteroids and sterilize the 
plant material was performed by P.L. Thomas, Inc. (Morristown, NJ, USA).  High-pressure 
liquid chromatography (HPLC) analysis of the sterilized and extracted A. turkestanica plant 
material, normalized to a 20E standard, revealed a 6% milligrams per milliliter (mg/mL) total 
phytoecdysteroid content in the initial extract.  The initial extract was air dried and sieved 
through a 60 millimeter (mm) mesh screen.  P.L. Thomas, Inc. kindly donated 500 grams (g) 
of the initial extract for this project and shipped it to the Appalachian State University’s 
Human Performance Laboratory in Kannapolis, NC. The initial extract was received and 
placed in a -20°C freezer until further extraction and analysis. 
Phytoecdysteroid Enrichment and Standardization.  Creation of an extract 
enriched in phytoecdysteroids from the initial ATE was performed using methods established 
by Cheng et al.145, with modifications.  Briefly, (1st extraction) 100 g of the initial extract 
was suspended in 500 mL of sterile double distilled water (ddH2O) and sonicated for 10 
minutes.  The suspension was defatted by partition (liquid-liquid extraction) with n-hexane 
(500 mL x 4).  The defatted aqueous layer was then partitioned with ethyl acetate (500 mL x 
8).  The combined ethyl acetate extract was dried over anhydrous sod-sulfate and solvent was 
removed via rotary evaporation to afford the ethyl acetate extract.  The dried ethyl acetate 
extract was analyzed by thin-layer chromatography (TLC) silica gel 60 F254 250 µm pre-
coated plates (EMD Chemicals, Inc.; Gibbstown, NJ, USA) with a solvent system of ethyl 
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acetate-methanol-water at 77:13:19 ratio.  The TLC plates were monitored by short wave 
ultraviolet lamps (254 nm) and visualized with vanillin reagent (4 g vanillin, 100 mL 
methanol and 2.5 mL H2SO4).148  Following identification of phytoecdysteroids by TLC 
visualization, HPLC analysis was performed for quantification of phytoecdysteroids.  A 
commercial HPLC grade standard of 20E (Sigma Aldrich; St. Louis, MO, USA) at 
concentrations of 250, 500, and 1000 µg/ml with 10 µL injection volumes was used to 
determine the concentrations of phytoecdysteroids in the extract.  Analysis was performed 
using an Agilant 1200 HPLC system (Agilent Technologies, Inc.; Wilmington, DE, USA) 
with autosampler, DAD (247 nm) and Synergi 4 um Hydro-RP 80A reversed phase column 
(250 mM x 4.6 mm x 5 um, Phenomenex; Torrance, CA, USA).  The mobile phase solvents 
consisted of 2% acetic acid in H2O (solvent A) and 0.5% acetic acid in 50% aqueous 
acetonitrile (solvent B). Gradients of 10%, 15%, 25%, 35%, 55%, 100%, and 10% of solvent 
B were used at 0, 10, 13, 20, 50, 54, and 60 minutes, respectively, with 1.0 mL/min flow rate.  
Samples were filtered through 0.2 mm PTFE filters (GE Healthcare; Pittsburg, PA, USA) 
before injecting 10 µl on the HPLC column (25°C).  Identification of phytoecdysteroids was 
performed in reference to compounds isolated previously from A. turkestanica.145 
Quantification of compounds was performed from the peak areas recorded at 247 nm for 
phytoecdysteroids in reference to the calibration curve obtained with a purified commercial 
20E standard (i.e., 100% total phytoecdysteroids).  Concentrations were calculated by taking 
the average of two HPLC runs. 
 The aqueous layer remaining after the ethyl acetate partition was then partitioned 
with butanol (750 mL x 3).  Butanol was removed via rotary evaporation and the residue 
obtained was freeze-dried to afford the butanol extract.  Following identification of 
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phytoecdysteroids by TLC visualization, HPLC analysis was performed for quantification of 
phytoecdysteroids. The aqueous layer after butanol extraction was discarded.  The dried 
butanol extract was pulverized with a porcelain mortar and pestle, heated in 60°C water bath 
and sonicated for 10 minutes to help dissolution and then vacuum filtered through Whatman 
#4 (GE Healthcare; Pittsburg, PA, USA).  One-half of the dried butanol extract was then 
extracted with 0.5% methanol in ethyl acetate (100 mL x 4).  The solvent was removed via 
rotary evaporation and the combined ethyl acetate extracts were dehydrated over anhydrous 
sod-sulfate and lyophilized.  Based on HPLC results, the 0.5% methanol in ethyl acetate 
dried extract was then combined with the remaining one-half dried butanol extract in a ratio 
of 2:3 (i.e., 2:3 mixture).  The 2:3 mixture was first extracted with methanol (100 mL x 4) 
and then butanol (100 mL x 4).  The solvents from the 2:3 extract were rotatory evaporated 
and lyophilized.  From the concentrations determined by HPLC, the dried methanol 2:3 
mixture extract and butanol 2:3 mixture extract were then combined to create a 1:4 ratio of 
20E to turkesterone, ATE.  The 1:4 ATE was analyzed by TLC as described above and then 
analyzed for phytoecdysteroid content by HPLC.  The final amount remaining from 
extraction was not sufficient for 28 days of supplementation, so a second extraction had to be 
performed (Figure 1). 
The 2nd extraction was simplified based on the results obtained from the 1st batch 
extraction.  Briefly, 100 g of the initial ATE was suspended in 500 mL of ddH2O and 
sonicated for 10 minutes.  The suspension was then partitioned with ethyl acetate (500 mL x 
10).  The ethyl acetate was dried over anhydrous sod-sulfate, the solvent was removed via 
rotary evaporation, and the residue was lyophilized.  The remaining aqueous layer was then 
extracted with butanol (500 mL x 5). The butanol was removed via rotary evaporation, and 
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the remaining residue was lyophilized.  The dried butanol extract was then pulverized, 
heated, sonicated, and filtered using the same methods described above.  The dried butanol 
extract was then extracted with 0.2% methanol in ethyl acetate (100 mL x 4).  The 0.2% 
methanol in ethyl acetate extract was dried over anhydrous sod-sulfate, the solvents were 
removed via rotary evaporation, and the residue was lyophilized.  From the concentrations 
determined by HPLC, the dried 0.2% methanol in ethyl acetate was then combined with the 
dried ethyl acetate and the 1:4 ATE from extraction 1 to create the final 1:4 ATE that was 
used for the supplementation protocol (Figure 2).  The final 1:4 ATE was analyzed by TLC 
as described above and then analyzed for phytoecdysteroid content by HPLC. 
 Experimental Design.  Aged male C57BL/6 (20 months-old) mice were 
supplemented with 50mg/kg/day of ATE, 20E, or vehicle only (CT) for 28 consecutive days 
(Figure 3).  Following 28 days of supplementation, a force-frequency curve and low-
frequency fatigue protocol were utilized to determine in vivo contractile function of the 
gastrocnemius-plantaris-soleus (GPS) complex.  Following contractile function 
measurements, animals were euthanized and skeletal muscle and organ tissues were 
harvested, weighed, and stored at -80°C until further analysis.  MPS and mitochondrial 
biogenesis pathway signaling analyses were performed on muscle lysates and muscle fiber 
cross-sectional area (CSA) analysis was performed on transverse sectioned muscle. 
Animals.  Male C57BL/6 mice (n = 36), 20-months old, were randomly assigned to 
one of three treatment groups: CT (50 mg/kg/day; n = 12), ATE (50 mg/kg/day; n = 12), or 
20E (50 mg/kg/day; n = 12).  The ATE used for the ATE treatment was from the enriched 
phytoecdysteroid extract described above, and 20-hydroxyecdysone (20E) was purchased 
from Bosche Scientific (E6425-HE; New Brunswick, NJ, USA).  ATE and 20E were 
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suspended in EtOH.  The ATE, 20E or CT was aliquoted onto one-190 mg rodent enrichment 
treat (Fruit Crunchies; BioServ, Frenchtown, NJ, USA) the day before feeding it to the 
animal in order to allow the EtOH to evaporate.  The previous day’s body mass was used to 
calculate the amount of ATE, 20E, or vehicle needed.  For example, the measured body mass 
of a given mouse on Sunday was used to calculate the volume of ATE or 20E (50 mg/kg) that 
was applied to the Fruit Crunchie, air dried, and fed to that mouse on Monday.  Mice were 
housed and tested within the David H. Murdock Research Institute Center for Laboratory 
Animal Sciences at the North Carolina Research Campus, Kannapolis, NC, an Association 
for Assessment and Accreditation of Laboratory Animal Care facility.  The room was 
maintained at 21°C, 50% humidity, with a 12:12-hour reverse light cycle.  Food and water 
were provided ad libitum.  At the end of each light cycle (0800 hours), body mass was 
measured.  Mice were then individually placed in an empty cage without bedding and fed one 
treated Fruit Crunchie. Complete consumption of the dosed Fruit Crunchie was visually 
confirmed for each mouse. All experiments were approved by the North Carolina Research 
Campus Institutional Animal Care and Use Committee and the experiments were conducted 
within the guidelines set forth by the American Physiological Society (Appendix A). 
In vivo Contractile Function.  In vivo determination of contractile function was 
obtained from the GPS complex.  Force output of the plantar flexors (i.e., GPS complex) was 
measured using a muscle lever system (Model 300C, Aurora Scientific; Aurora, ON, Canada) 
as previously described.149  Briefly, each mouse was initially anesthetized with 4% inhaled 
isofluorane with 800 mL oxygen (O2) output and maintained at 2% inhaled isofluorane with 
500 mL O2 output for the entire contractile function data collection period.  Hair was 
removed from both hindlimbs with a standard depilatory product (NairTM) and placed on a 
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heated platform (37°C).  The knee joint was kept stationary and the foot was firmly fixed to a 
footplate with adhesive wrapping, which was connected to the shaft of the force transducer 
(Model 402A, Aurora Scientific; Aurora, ON, Canada).  Contraction of the GPS complex 
was elicited by electrical stimulation using a model 701C stimulator (Aurora Scientific; 
Aurora, ON, Canada) via needle electrodes (Model F-E7-30, Grass Technologies; West 
Warwick, RI) inserted parallel to the tibial nerve.  Electrode placement was tested via short 
stimulation of the nerve to cause plantar flexion.  When stimulated, the foot was checked for 
plantar flexion without any visible eversion or inversion of the foot.   
Force-Frequency Curve and Fatigue Protocol.  Optimal voltage (Vo) and optimal 
length (Lo) were determined as the maximal voltage and length that produced the greatest 
amount of force during a single submaximal twitch contraction.  A force-frequency curve 
was then determined by stimulating the GPS complex with single 500 ms trains, 200 µsec 
pulses every 3 minutes at increasing stimulation frequencies (1, 15, 30, 60, 100, 160 Hertz; 
Hz).  At five minutes post force-frequency, a low-frequency fatigue protocol was 
implemented (250 ms trains, 200 µsec pulses every 3.5 seconds at 30 Hz for 30 minutes).  At 
five minutes post low-frequency fatigue protocol, a single 100 Hz contraction was performed 
to determine fatigue level following the protocol. 
Data Acquisition and Analysis.  The muscle lever system, stimulator and force 
transducer were connected to a signal interface (Model 604A, Aurora Scientific; Aurora, ON, 
Canada) that sent the analog signal to an analog to digital convertor card (Model PCI-6221, 
National Instruments; Austin, TX, USA) on a computer with Dynamic Muscle Control 
software (Aurora Scientific; Aurora, ON, Canada).  Force output data was analyzed using 
Dynamic Muscle Analysis software (Aurora Scientific; Aurora, ON, Canada). 
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Dissection of Skeletal Muscles and Organs.  Following the contractile function 
procedure mice were euthanized by exsanguination via cardiac puncture.  Skeletal muscles 
were dissected from both contracted and non-contracted hindlimbs (including extensor 
digitorum longus, tibialis anterior, soleus, plantaris, gastrocnemius, and quadriceps) and wet 
weight (mass) was measured.  Triceps brachii muscles were dissected from front limbs.  In 
addition, organs (including heart, liver, spleen, kidneys, and testes) were removed and wet 
weight was measured.  Skeletal muscles and organs were immediately snap frozen in liquid 
nitrogen (N2) or liquid N2 cooled isopentane (plantaris and triceps brachii) and stored at -
80°C freezer until subsequent analysis.   
Western Blotting.  Both hindlimb contracted and non-contracted gastrocnemius (100 
mg) were pulverized on dry ice using a porcelain mortar and pestle and homogenized on ice 
in 0.3 mL of homogenization buffer containing 1.0 mM NaCl, 1.0% Triton-X, 0.5% sodium 
deoxycholate, 10 mM Tris-HCl, pH 7.6 with protease and phosphatase inhibitor cocktails 
(Sigma Aldrich; St. Louis, MO, USA).  After homogenization, the samples were cleared by 
centrifugation for 15 min at 5,000 x gravity.  The supernatant was removed and protein 
concentration was determined using the BCA protein assay (Pierce; Thermo Fisher 
Scientific, Inc.; Rockford, IL, USA).  Total protein (30 µg) was prepared in Laemmli buffer 
and subjected to electrophoretic separation by SDS-PAGE on 7.5% acrylamide gels (#116-11 
18; Bio-Rad; Hercules, CA, USA) as previously described.150  Following electrophoretic 
separation, the proteins were transferred to a polyvinylidene difluoride (PVDF) membrane 
(Millipore; Bradford, MA, USA) and stained with 0.1% Ponceau S in 0.5% acetic acid 
(Sigma Aldrich; St. Louis, MO, USA) to ensure equal loading and transferring of proteins.  
The SNAP i.d. protein detection system (Millipore; Bradford, MA, USA) was used for 
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blocking and antibody incubation as previously described.151  Briefly, non-specific binding 
was blocked with 1% bovine serum albumin (BSA) in TBS-T (Tris buffered saline, 0.1% 
Tween 20) and immediately vacuumed through.  Following blocking, the membrane was 
washed three times and immediately vacuumed through with TBS-T and exposed to the 
following primary antibodies in 1% BSA/TBS-T for 10 minutes at room temperature: 
phosphorylated p70S6kThr389 (Cell Signaling; Danver, MA, USA - 9234; 1:500); total p70S6k 
(Cell Signaling; Danver, MA, USA - 2708; 1:1000); phosphorylated AktSer473 (Cell 
Signaling; Danver, MA, USA - 9271; 1:500); total Akt (Cell Signaling; Danver, MA, USA - 
9272; 1:1000); phosphorylated AMPKThr172 (Cell Signaling; Danver, MA, USA - 2531; 
1:500); total AMPK (Cell Signaling; Danver, MA, USA - 2532; 1:1000); phosphorylated 
p38-MAPKThr180/Tyr182 (Cell Signaling; Danver, MA, USA - 9210, 1:2500); and total p38-
MAPK (Cell Signaling; Danver, MA, USA - 9212, 1:5000).  The primary antibody was 
vacuumed through, the membrane was washed three times, and was immediately vacuumed 
through with TBS-T.  The membrane was then incubated for 10 minutes with horseradish 
peroxidase (HRP)-linked IgG anti-rabbit (Cell Signaling; Danver, MA, USA - 7074; 1:2000) 
secondary antibody and vacuumed through.  The membrane was then washed three times and 
immediately vacuumed through with TBS-T.  Membranes were exposed to SuperSignal West 
Dura ECL chemiluinescent detection HRP reagents (Pierce; Thermo Fisher Scientific, Inc.; 
Rockford, IL, USA) mixed 1:1 for 5 minutes.  Membranes were covered in plastic wrap and 
exposed to radiographic film.  Films were developed in a dark room using Konica Minolta 
SRX-101A film processor (Konica Minolta; Ramsey, NJ, USA).  Densitometry of specific 
protein target bands was determined using Image J software (National Institutes of Health; 
Bethesda, MD, USA).  All values obtained from one blot were normalized to the blot average 
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density.  Membranes were stripped with Restore western blot stripping buffer (Thermo 
Fisher Scientific, Inc.; Rockford, IL, USA) for 10 minutes, washed with TBS-T and re-
probed for additional antibodies as outlined earlier.  Complete stripping of antibodies was 
verified by application of the secondary antibody to the blot and developed as described 
above. 
Histological Analysis.  Non-contracted plantaris and triceps brachii muscles were 
mounted on cork in a tragacanth gum/optimal cutting temperature (OCT, Thermo Fisher 
Scientific, Inc.; Rockford, IL, USA) mixture and frozen in liquid N2-cooled isopentane.  
Muscles were then cut into 10 µm cross-sections using a cryoSTAT (Model Microm HM 
505, Thermo Fisher Scientific, Inc.; Rockford, IL, USA).  The cross-sections were stained 
with hemotoxylin and eosin (H&E) and light micrographs were captured (10X) with an 
Olympus IX81 microscope (Olympus America, Inc.; Center Valley, PA, USA).  Muscle fiber 
CSA of ~200 muscle fibers for each section were measured with Olympus MicroSuite 
software (Olympus America, Inc.; Center Valley, PA, USA) by three individual investigators 
blinded to the treatment.  
Statistical Analysis.  A 1 x 3 (maximal tetanic force x treatment) one-way ANOVA 
was performed to determine differences between maximal force output (grams) amongst 
treatments for the force-frequency curve.  A 1 x 3 (fatigue index x treatment) one-way 
ANOVA was performed to determine differences between fatigue index (%), the percent 
difference from the maximal tetanic tension force output during the force-frequency curve 
and the tetanic tension force output from a single 100 Hz contraction after 5 minutes of rest 
following the fatigue protocol between treatments.  A 1 x 3 one-way ANOVA was performed 
to determine if differences exist in phosphorylation status of AMPK, p38-MAPK, Akt, and 
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p70S6K in the non-contracted gastrocnemius muscles with treatment.  Additionally, a 1 x 3 
(contraction x treatment) repeated measures two-way ANOVA was performed to determine 
if differences exist in contraction-induced phosphorylation status of AMPK, p38-MAPK, 
Akt, and p70S6K in the gastrocnemius muscle with treatment.  A 1 x 3 one-way ANOVA 
was performed to determine if differences exist in CSA (µm) of the triceps brachii and 
plantaris muscles with treatment.  A 1 x 3 one-way ANOVA was performed to determine 
differences between muscle or organ wet weight (normalized to grams of body mass) 
between treatments.  Following a significant F-ratio, Tukey’s post-hoc analyses were 
performed to determine where specific differences in conditions or treatments occurred.  
Significance was determined, a priori, at a p-value of ≤ 0.05, and GraphPad Prism 5 
(GraphPad; La Jolla, CA, USA) software was used for the analyses.   
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CHAPTER 3: RESULTS 
	  
Isolation of Phytoecdysteroids from A. turkestanica.  The 200 g (100 g x 2) ethyl 
acetate, butanol, and methanolic extraction of initial dried A. turkestanica plant material 
yielded a 3.89 g enriched phytoecdysteroid extract.  TLC analysis of the final 1:4 ATE 
revealed that the major phytoecdysteroid compounds were present in the extract.  Peak run 
time (Rt) identities were recorded at a wavelength of 247nm for the identified 
phytoecdysteroids: turkesterone (Rt 22.7 min), 20E (Rt 29.6 min), cyasterone (Rt 36.7 min), 
ajugasterone (Rt  40.3 min), ajugalactone (Rt 50.0 min), and cyasterone 22-acetate (Rt 51.9 
min), determined by HPLC (Figure 4).  These results are consistent with the commercial 
standards.  The identified phytoecdysteroids contained within the 1:4 ATE dry weight 
included: turkesterone (5.85%, 0.29 mg/mL), 20E (23.61%, 1.18 mg/mL), cyasterone 
(3.07%, 0.15 mg/mL), ajugasterone (2.02%, 0.10 mg/mL), ajugalactone (3.98%, 0.20 
mg/mL), and cyasterone 22-acetate (2.23%, 0.11 mg/mL; Figure 5).  Peak identity of the 
commercial 20E used for supplementation occurred at Rt 29.4 min and contained 80.11% 
total phytoecdysteroid and 0.4 mg/mL dry weight, determined by HPLC (Figure 5).  
Body, Muscle, and Organ Mass.  Body mass was determined for each treatment 
prior to day 1 and day 28 of supplementation.  No significant differences (NSD; p > 0.05) 
were observed in body mass between CT, ATE, and 20E on day 1 and day 28; 32.7 ± 1.0 g, 
33.0 ± 0.9 g, 33.4 ± 0.4 g and 32.4 ± 1.1 g, 32.8 ± 0.7 g, 32.5 ± 0.6 g, respectively (Table 1).  
Skeletal muscle and organ wet mass were determined as mass of muscle tissue (mg) 
normalized to total body mass (mg/g body mass).  NSD (p > 0.05) were observed in muscle 
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tissue wet mass/body mass between CT, ATE, and 20E in the soleus, plantaris, 
gastrocnemius, tibialis anterior, or extensor digitorum longus muscles (Table 2).  In addition, 
NSD (p > 0.05) were observed in organ tissue wet mass/body mass between CT, ATE, and 
20E for the heart, liver, spleen, kidneys, and testes (Table 3). 
In vivo Contractile Function.  Twitch tension was determined as the force during a 
single stimulated submaximal twitch (1 Hz) contraction and force output data are presented 
as Newtons per gram of GPS mass (N/g GPS).  There were NSD (p > 0.05) in twitch tension 
between CT, ATE, and 20E; 11.6 ± 0.7 N/g GPS, 10.2 ± 1.0 N/g GPS, 10.8 ± 0.8 N/g GPS, 
respectively.  Maximal tetanic tension was determined as the highest force output achieved 
during the force-frequency curve.  The average maximal tetanic tension for all animals 
occurred between 60 to 100 Hz.  Maximal tetanic tension force output data are presented as 
N/g GPS. There were NSD (p > 0.05) in maximal tetanic tension between CT, ATE, and 
20E; 42.8 ± 2.7 N/g GPS, 41.4 ± 3.5 N/g GPS, 34.8 ± 3.0 N/g GPS, respectively.  Fatigue 
index (%) was determined as the percent difference from the maximal tetanic tension force 
output during the force-frequency curve and the tetanic tension force output from a single 
100Hz contraction after 5 minutes of rest following the fatigue protocol.  There were NSD (p 
> 0.05) in fatigue index (%) between CT, ATE, and 20E; 23.1 ± 2.4%, 21.2 ± 2.0%, 23.6 ± 
1.7%, respectively (Table 4). 
Muscle Fiber Cross-Sectional Area.  Plantaris and triceps brachii muscle cross-
sections were visualized using H&E staining techniques.  Each muscle fiber cross-sectional 
area was measured on ~200 complete muscle fibers from digital images of H&E stained 
muscle cross-sections.  Results revealed that 20E-treated mice had 30% larger plantaris 
muscle fiber CSA, compared to CT (p = 0.018; 2180.0 ± 152.4 µm2 versus 1676.9 ± 138.4 
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µm2); however plantaris muscle fiber CSA in ATE-treated mice was not significantly 
different than CT (p = 0.497; 1810.5 ± 114.4 µm2 versus 1676.9 ± 138.4 µm2; Figure 6A and 
6B).  Furthermore, 20E-treated mice had 41% larger triceps brachii muscle fiber CSA, 
compared to CT (p = 0.014; 2557.2 ± 209.8 µm2 versus 1811.0 ± 90.0 µm2).  Triceps brachii 
muscle fiber CSA in ATE-treated mice tended to be larger, but was not significantly different 
than CT (p = 0.088; 2285.4 ± 215.6 µm2 versus 1811.0 ± 90.0 µm2; Figure 6C and 6D). 
Protein Synthesis Pathway Signaling.  Markers for protein synthesis pathway 
signaling activity (Akt and p70S6k) were measured by Western blot analysis and determined 
as the density (arbitrary units; AU) of the target protein band, normalized to the blot average.  
Total measured samples for non-contracted limb treatment for the phosphorylation status of 
AktSer473 and p70S6kThr389 was n = 6 for each group.  NSD (p > 0.05) were observed in 
phosphorylation status of AktSer473 and p70S6kThr389 in basal (non-contracted) skeletal 
muscles between CT, ATE and 20E (Figures 7A and 7B, respectively).  Further, NSD (p > 
0.05) were observed in contraction-induced (contracted versus non-contracted; C:NC) 
phosphorylation status of AktSer473 and p70S6kThr389 between CT, ATE, and 20E (Figures 7C 
and 7D, respectively).  NSD (p > 0.05) were seen between CT, ATE, and 20E for total 
protein content of non-contracted Akt and p70S6k (Figures 8A and 8B, respectively) and 
contraction-induced Akt and p70S6k (Figures 8C and 8D, respectively).  
Mitochondrial Biogenesis Pathway Signaling.  Upstream markers for mitochondrial 
biogenesis pathway signaling (AMPK and p38-MAPK) were measured by Western blot 
analysis and determined as the density (AU) of the target protein band, normalized to the blot 
average.  Total measured samples for non-contracted limb treatment for the phosphorylation 
status of AMPKThr172 and p38-MAPKThr180/Tyr182 was n = 6 for each group.  NSD (p > 0.05) 
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were observed in phosphorylation status of AMPKThr172 and p38-MAPKThr180/Tyr182 in basal 
(non-contracted) skeletal muscles between CT, ATE, and 20E (Figures 9A and 9B, 
respectively).  Further, NSD (p > 0.05) were observed in contraction-induced (C:NC) 
phosphorylation status of p38-MAPKThr180/Tyr182 (Figure 9C); however, there was a 
significant increase (p < 0.001) in contraction-induced phosphorylation of AMPKThr172 in 
20E-treated mice, compared to CT and ATE (Figure 9D).  NSD (p > 0.05) were seen 
between CT, ATE. and 20E for total protein content of non-contracted AMPK and p38-
MAPK (Figures 10A and 10B, respectively) and contraction-induced AMPK and p38-MAPK 
(Figures 10C and 10D, respectively). 
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CHAPTER 4: DISCUSSION 
 
The purpose of the current study was to determine the effects of ATE, 20E, or vehicle 
only (CT) fed to 20-month old male mice for 28 days on their ability to (1) increase strength 
and muscle mass, (2) activate the key control point of protein synthesis, the PI3k-Akt 
pathway, and (3) activate key upstream control points for mitochondrial biogenesis, the 
AMPK and p38-MAPK pathways.  The novel findings of this study were the increase in 
muscle fiber size and contraction-induced AMPK activation in aged mouse skeletal muscle 
with 20E supplementation. 
Anabolic Effects of Phytoecdysteroids in Aged Muscle.  The anabolic effects of 
20E supplementation are well documented.10,35,137-139,140,142,152  There are conflicting results 
between 20E supplementation and increases in muscle and body mass.142,152-153  The 
variances in anabolic effects lie within the differences in route, dose, length of treatment, and 
strain or species of 20E administration.  Further, all previous studies that have reported 
anabolic effects of phytoecdysteroids in rodents have all been in young animals.140,142,152  
This is the first study to demonstrate the effects of 28 days of phytoecdysteroid 
supplementation on aged mouse skeletal muscle. 
20E-treated sedentary aged mice had a significant 30% and 41% larger fiber CSA of 
plantaris and triceps brachii muscles, respectively, compared to CT.  The increases in muscle 
fiber CSA are similar to the findings of Toth et al.142, who reported significant increases in 
extensor digitorum longus and soleus muscle fiber CSA when young rats were administered 
subcutaneous injections of 20E (5 mg/kg/day) for 8 days. Additionally, the authors 
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demonstrated that 20E increases fiber size in a muscle-specific fashion (i.e., dependent on the 
fiber type composition of the muscle), with type I and IIa (i.e., slower, smaller force 
producing fiber subtype and larger, faster force producing subtype, respectively) and IIx (i.e., 
fastest, largest force producing fiber subtype) demonstrating the greatest gains in CSA, in 
soleus and extensor digitorum longus muscles, respectively.142 
ATE supplemented mice had a non-significant 8% and 26% increase in fiber CSA of 
plantaris (p = 0.497) and triceps brachii (p = 0.088) muscles, respectively, compared to CT.  
The lack of significance in plantaris and triceps brachii in fiber CSA of ATE is an interesting 
finding.  The 50 mg/kg/day dose of phytoecdysteroids of the ATE treated mice contained 
28.96 mg/kg/day 20E.  Whereas the 20E treated mice received 50 mg/kg/day 20E, which is a 
difference of 21.04 mg/kg/day (Figure 5).  This may partially explain the differences in both 
signaling and fiber CSA between ATE and 20E.  Toth et al.142 demonstrated that the 
increases in body and muscle mass were greater with 5 mg/kg dosages than 0.5 mg/kg 
dosages of subcutaneous injections of 20E.  In addition, Gorelick-Feldman et al.35 
demonstrated that 20E increased Akt phosphorylation in a dose-dependent (i.e., from 0-10 
µM) manner in C2C12 cells.  Taken together, a higher dosage of 20E in the ATE treatment 
may have been required in order to see increases in muscle fiber size and signaling. 
The mechanisms for increases in muscle fiber size with age are believed to be due, in 
part, to either increases in anabolic or protein synthesis signaling (i.e., PI3k-Akt signaling) or 
transitions from slower, smaller fiber subtypes (i.e., type I) to faster, larger fiber subtypes 
(i.e., type IIa and IIb or IIx).  The effect of phytoecdysteroid treatment on fiber type is 
currently being analyzed in our lab.  To test PI3k-Akt signaling, upstream (i.e., AktSer473) and 
downstream (i.e., p70S6kThr389) markers for this pathway were analyzed in both non-
	  45	  
contracted and contracted GPS.  We were unable to detect differences in non-contracted or 
contracted limb phosphorylation of either AktSer473 or p70S6kThr389 between treatments.  
While 20E and ATE have been found to work through the PI3k-Akt pathway,35,140 no study 
has investigated activation of this pathway by phytoecdysteroid treatment from in vivo 
supplementation.  In the current study, the increases in fiber CSA seen with 20E would 
suggest activation of anabolic (i.e., PI3k-Akt) signaling.  The reason for no differences in 
non-contracted PI3k-Akt signaling could have been due to missed peak signaling for both 
Akt and p70S6k.  The animals were not supplemented the day of contractile function and 
sacrifice (i.e., day 29).  Therefore, we hypothesize that the acute signaling response of 
phytoecdysteroid supplementation was missed.  In support of this muscle protein synthesis, 
signaling through the PI3k-Akt pathway has been shown to peak within 45-90 minutes 
following oral feeding of the amino acid leucine, an activator of the PI3k-Akt pathway, in 
young animals.154  In addition, 20E has been found to be eliminated rapidly in young mice.  
Dzhukharova et al.155 reported that a 50 mg/kg caudal vein infusion of 20E with radioactively 
labeled 3H-thymidine had ~90% eliminated in 30 minutes.  The authors also reported that 
20E has a half-life of 8.15 min.155  This may explain the reason behind the missed signaling 
differences of the PI3k-Akt pathway between treatments.  However, the goal of the current 
study was to examine the chronic (i.e., multiple days; 28 days) and not acute (i.e., single day 
or hours) effects of phytoecdysteroid supplementation on PI3k-Akt signaling.  Future 
investigations should examine the acute effects of 20E supplementation of PI3k-Akt 
signaling in aged skeletal muscle. 
There were no differences between treatments in contracted gastrocnemius 
phosphorylation of Akt and p70S6k.  These findings are similar to other studies.89,156  
	  46	  
Skeletal muscle has been shown to have two distinct pathways involved in hypertrophy or 
anabolic signaling and energy or mitochondrial signaling.88,156-157  With the 30 minute low-
frequency fatigue protocol, it can be speculated that there were high AMP:ATP ratios 
creating a low cellular energy state.  During low cellular energy states, AMPK will directly 
inhibit large energy consuming pathways (i.e., PI3k-Akt) and up-regulate pathways involved 
in increasing cellular energy production (i.e., mitochondrial biogenesis).157  Therefore, that 
no differences were seen in PI3k-Akt signaling following contraction was to be expected. 
Phytoecdysteroids Effects on Mitochondrial Biogenesis Pathway Activation.  To 
test the effects of phytoecdysteroid supplementation on increasing mitochondrial biogenesis, 
two upstream markers (i.e., p38-MAPKThr180/Tyr182 and AMPKThr172) that are directly linked to 
activating the “master regulator” of mitochondrial biogenesis, peroxisome proliferators-
activated receptor co-activator 1 (PGC-1α), were analyzed.  No differences were seen 
between treatments in non-contracted limb phosphorylation of p38- MAPKThr180/Tyr182 and 
AMPKThr172.  The acute signaling response for these two markers has been found to peak 
within 30-60 minutes following pharmaceutical activation via 5-aminoimidazole-4-
carboxamide-1-beta-D-ribofuranoside (AICAR) in skeletal muscle.158,159  Therefore, with the 
rapid elimination of 20E demonstrated by Dzhukharova et al.155 may explain the reason for 
the no differences in resting mitochondrial biogenesis signaling.  Again, the goal of the 
current investigation was to examine the effects of chronic (i.e., 28 days) mitochondrial 
biogenesis signaling and not acute (i.e., single day or hours) mitochondrial biogenesis 
signaling.  Future investigations should examine the acute effects of phytoecdysteroid 
supplementation on mitochondrial biogenesis signaling in aged skeletal muscle.   
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AMPK’s low energy sensing ability is impaired with aging.6-7,76  In the current study, 
20E treated mice were able to activate AMPK following a 30 minute low-frequency fatigue 
protocol.  Therefore, one can speculate that 20E may be able to correct AMPK’s sensing 
ability in aged muscle.  However, further research is needed to either prove or disprove this 
finding.  Conversely, no differences were observed in p38-MAPKThr180/Tyr182 phosphorylation 
following the low-frequency fatigue protocol.  p38-MAPK has been found to be activated 
during low cellular energy states to subsequently activate molecules (i.e., PGC-1α) involved 
in increasing cellular energy production (i.e., mitochondrial biogenesis).92  It is interesting 
that 20E was able to activate AMPK following contraction, but not p38-MAPK.  However, 
these findings are similar to Ljubicic and Hood.6  The authors demonstrated a difference in 
high oxidative red muscle (i.e., high mitochondrial content) and low oxidative white muscle 
(i.e., low mitochondrial content) activation of AMPK and p38-MAPK following a low-
frequency fatigue protocol of 1 Hz for 5 minutes of muscle isolated from the tibialis anterior 
(TA) of aged rats.  Only the high oxidative red TA muscle was shown to activate both p38-
MAPKThr180/Tyr182 and AMPKThr172 following the fatigue protocol.  In addition, the isolated 
low oxidative white TA muscle did not activate either p38 MAPKThr180/Tyr182 or AMPKThr172 
following the fatigue protocol.  In the current study, the entire gastrocnemius muscle, a 
predominantly low oxidative muscle, was utilized for mitochondrial biogenesis pathway 
signaling.  The use of the entire gastrocnemius muscle may partially explain the reason for no 
differences in p38 MAPKThr180/Tyr182 activation following the fatigue protocol.  Conversely, 
the observed AMPKThr172 activation by 20E following the fatigue protocol is opposite of the 
findings by Ljubicic and Hood.6  The differences between AMPK activation in low oxidative 
muscle by Ljubicic and Hood6 and the current study could be due to the frequency (1 Hz 
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versus 30 Hz) and duration (5 minutes versus 30 minutes) of the fatigue protocols.  More 
research is needed to analyze the effects of phytoecdysteroid treatment on contraction-
induced mitochondrial biogenesis signaling, specifically in determining the differences in 
both low and high oxidative muscles/fibers.    
Novel Method for Dietary Phytoecdysteroid Supplementation.  To minimize 
distress and chance of injury to the animals, a new method for phytoecdysteroid 
supplementation was employed.  The method of applying the 50 mg/kg/day dosage of either 
vehicle only (CT), ATE, or 20E to one-190 mg rodent enrichment treat (Fruit Crunchies, 
BioServ; Frenchtown, NJ, USA) one-day prior to supplementation proved to be very 
effective.  This newly established method could be of great use for investigators in order to 
dose mice with phytoecdysteroids solubilized in non-denatured ethanol for long 
supplementation protocols and to minimize stress and chance of injury, especially in aged 
rodents where there is an even greater concern due to the high mortality rates of aged 
animals.   
CONCLUSIONS 
This is the first study to demonstrate that 20E increases muscle fiber CSA in 21-
month old male mice.  In addition, we report that 20E increases contraction-induced AMPK 
activity in aged mouse skeletal muscle.  However, further research is needed to determine the 
consequence of this finding on mitochondrial biogenesis.  Further, 20E may be a potent, non-
hormonal countermeasure to reverse the loss of muscle mass that occurs with aging.  
Findings from this study warrant further research on phytoecdysteroids effects on the age-
associated loss of muscle mass. 
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Table	  1.	  Animal	  mass	  data.	  
  Treatment            Body Mass Day 1 (g)    Body Mass Day 28 (g)      P-value 
 
CT 
 
32.7 ± 1.0 
 
32.4 ± 1.1 
 
0.44 
 
ATE 
 
33.0 ± 0.9 
 
32.8 ± 0.7 
 
0.40 
 
20E 
 
33.4 ± 0.4 
 
32.5 ± 0.6 
 
0.12 
 
Data are presented as mean (grams; g) ± standard error of the mean by treatment: control 
(CT), Ajuga turkestanica extract (ATE) and 20-hydroxyecdysone (20E).  No significant 
differences between groups, p > 0.05. 
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Table 2. Muscle wet weight of non-contracted hindlimb. 
Muscle CT ATE 20E P-value 
 
Soleus 
 
0.27 ± 0.00 
 
0.27 ± 0.01 
 
0.28 ± 0.00 
 
0.36 
 
Plantaris 
 
0.62 ± 0.01 
 
0.60 ± 0.01 
 
0.65 ± 0.02 
 
0.27 
 
Gastrocnemius 
 
4.13 ± 0.13 
 
3.96 ± 0.11 
 
4.07 ± 0.11 
 
0.60 
 
Tibialis Anterior 
 
 
1.74 ± 0.08 
 
 
1.69 ± 0.03 
 
 
1.74 ± 0.03 
 
 
0.72 
 
Extensor 
Digitorum Longus 
0.39 ± 0.02  
 
0.36 ± 0.01 
 
0.36 ± 0.10 
 
0.50 
 
 
Data are presented as mean (mg tissue/g body mass) ± standard error of the mean by 
treatment: control (CT), Ajuga turkestanica extract (ATE) and 20-hydroxyecdysone (20E).  
No significant differences between groups, p > 0.05. 
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Table 3. Organ wet weight data. 
Organ            CT           ATE           20E        P-value 
 
Heart 
 
5.0 ± 0.2 
 
4.8 ± 0.2 
 
4.9 ± 0.1 
 
0.66 
 
Liver 
 
46.4 ± 3.6 
 
40.4 ± 0.9 
 
41.6 ± 1.2 
 
0.16 
 
Spleen 
 
3.8 ± 1.4 
 
2.4 ± 0.2 
 
2.6 ± 0.1 
 
0.47 
 
Kidneys 
 
13.6 ± 0.4 
 
14.1 ± 0.5 
 
14.5 ± 0.5 
 
0.44 
 
Testes 
 
5.7 ± 0.2 
 
 5.5 ± 0.1 
 
 5.4 ± 0.1 
 
0.57 
 
Data are presented as mean (mg tissue/g body mass) ± standard error of the mean by 
treatment: control (CT), Ajuga turkestanica extract (ATE) and 20-hydroxyecdysone (20E).  
No significant differences between groups, p > 0.05. 
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Table 4. In vivo contractile function data of the gastrocnemius-plantaris-soleus (GPS) 
complex.  
Contractile Measurement CT ATE    20E      P-value 
 
Twitch Tension  
 
11.6 ± 0.7 
 
10.2 ± 0.2 
 
10.8 ± 0.8 
 
0.51 
 
Maximal Tetanic Tension 
 
42.8 ± 2.7 
 
41.4 ± 3.6 
 
34.8 ± 3.0 
 
0.16 
 
Fatigue Index (%) 
 
23.1 ± 2.4 
 
21.2 ± 2.0 
 
23.6 ± 1.7 
 
0.67 
 
Data are presented as mean (Newtons per gram of GPS mass; N/g GPS) ± standard error of 
the mean by treatment: control (CT), Ajuga turkestanica extract (ATE) and 20-
hydroxyecdysone (20E).  No significant differences between groups, p > 0.05. 
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FIGURE 1. Ajuga turkestanica 1st batch flow chart. The first extraction of the 6% “crude” 
A. turkestanica extract was suspended in double distilled water (ddH2O) and partitioned with 
n-hexane.  The n-hexane layer was then discarded.  The remaining aqueous (AQ) layer was 
partitioned with ethyl acetate (EthAc).  The ethyl acetate extract (6.27 g) was dried and set 
aside. The remaining AQ layer was then extracted with butanol (BuOH).  The BuOH extract 
(35.13 g) was split and ½ of the extract (17.57 g) was extracted with EthAc in 0.5% methanol 
(MeOH).  The 0.5% MeOH in EthAc extract (2.47 g) was then combined with 1.64 g of the 
remaining ½ BuOH extract at 2:3 EthAc extract to BuOH extract ratio (i.e., 2:3 mixture) to 
obtain a 1:4 20E to turkesterone ratio. The 2:3 mixture was then extracted first with EthAc 
and then BuOH.  The EthAc extract (1.65 g) was dried and combined with the dried BuOH 
extract (0.99 g) to make a 1:4 20E to turkesterone ratio.   
 
 
 
 
 
AQ Layer 
6% A. turkestanica Crude Extract (100 g) 
suspended in 500 mL ddH2O 
6% A. turkestanica Extract (500 mL) 
partition with n-hexane (500 mL x 4) 
partition with EthAc (500 mL x 8) 
EthAc Extract (6.27 g) AQ Layer 
extract with BuOH (750 mL x 3) 
AQ Layer BuOH Extract (35.13 g) 
½ BuOH extract with 0.5% MeOH in EthAc (100 mL x 4) 
0.5% MeOH in EthAc Extract (2.47 g) ½ BuOH Extract (17.57 g) 
2.47 g 1.64 g Combined for 2:3 Mixture 
2:3 Mixture (4.11 g) 
extract 1st with MeOH (100 mL x 4) and 2nd BuOH (100 mL x 4) 
MeOH Extract (1.65 g) BuOH Extract (0.99 g) 
1st Extraction 1:4 Mixture (1.31 g) 
1.65 g 0.99 g Combined for 1:4 Mixture 
n-Hexane Layer 
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FIGURE 2. Ajuga turkestanica 2nd batch flow chart. The second extraction of 6% “crude” 
A. turkestanica extract (ATE) was suspended in double distilled water (ddH2O) and 
partitioned with ethyl acetate (EthAc). The EthAc extract (6.79 g) was dried and set aside.  
The remaining aqueous (AQ) layer was then partitioned with butanol (BuOH).  The AQ layer 
from the BuOH partitioning was discarded. The dried BuOH extract was then extracted with 
0.2% methanol (MeOH) in EthAc.  The 0.2% MeOH in EthAc extract (1.02 g) was then 
combined with the EthAc extract (1.56 g) and the 1st extraction 1:4 mixture (1.31 g) to create 
a final 1:4 ATE (3.89 g).  TLC analysis of the final 1:4 ATE revealed that the major 
phytoecdysteroid compounds were present in the extract. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EthAc Extract (6.79 g) 
6% A. turkestanica Crude Extract (100 g) 
suspended in 500 mL ddH2O 
6% A. turkestanica Extract (500 mL) 
partition with EthAc (500 mL x 10) 
EthAc Extract (6.79 g) AQ Layer 
extract with BuOH (500 mL x 5) 
AQ Layer BuOH Extract (17.01 g) 
extract with 0.2% MeOH + EthAc (100 mL x 4) 
1.02 g 1.56 g Combined for 1:4 Mixture 
Final 1:4 ATE (3.89 g) 
0.2% MeOH + EthAc Extract (1.02 g) 
1st Extraction 1:4 Mixture (1.31 g) 
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FIGURE 3.  Experimental design schematic. The effects of phytoecdysteroid 
supplementation on 20-month old male mouse skeletal muscle was tested.  Three treatment 
groups were employed for the 28-day supplementation protocol: control (CT; vehicle only of 
100% non-denatured ethanol, EtOH), Ajuga turkestanica extract (ATE), and 20-
hydroxecdysone (20E).  Following 28 days of consecutive supplementation with ATE, 20E, 
or vehicle only (CT) each animal was tested for in vivo contractile function of the 
gastrocnemius-plantaris-soleus (GPS) complex.  Skeletal muscles and organs were then 
dissected and utilized for Western blot analysis, muscle and organ wet weights, or 
histological and cross-sectional area (CSA) analysis. 
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 FIGURE 4. HPLC chromatogram of the final Ajuga turkestanica extract (ATE).  Peak run 
time (Rt) identities were recorded at a wavelength of 247nm for the identified 
phytoecdysteroids: turkesterone (Rt 22.7 min), 20E (Rt 29.6 min), cyasterone (Rt 36.7 min), 
ajugasterone (Rt  40.3 min), ajugalactone (Rt 50.0 min), and cyasterone 22-acetate (Rt 51.9 
min). 
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FIGURE 5.  ATE and 20E phytoecdysteroid contents. The commercial 20-hydroxecdysone 
(20E; i.e., 80.11% total phytoecdysteroid) utilized for the supplementation protocol was 
different from the purified commercial 20E (i.e., 100% total phytoecdysteroid) utilized for 
the phytoecdysteroid quantification calibration curve.  The identified phytoecdysteroids 
contained within the 1:4 Ajuga turkestanica extract (ATE) dry weight include: turkesterone 
(5.85%), 20E (23.61%), cyasterone (3.07%), ajugasterone (2.02%), ajugalactone (3.98%), 
and cyasterone 22-acetate (2.23%) for a total of 40.77% total phytoecdysteroid.  The 
commercial 20E used for supplementation contained 80.11% total phytoecdysteroid based on 
dry weight, as determined by HPLC. 
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FIGURE 6.  Plantaris and Triceps Brachii fiber cross-sectional area (CSA).  Skeletal muscle 
fiber CSA in 20-month old male mice after the 28-day supplementation period by treatment: 
control (CT), Ajuga turkestanica extract (ATE), and 20-hydroxyecdysone (20E). 
Quantification of CSA from ~200 fibers in Plantaris (A) and Triceps Brachii (B) muscles, 
respectively. Representative Hemotoxylin and Eosin stained sections from Plantaris (C) and 
Triceps Brachii (D) muscles, respectively. *Denotes 20E significantly different from CT (p < 
0.05). 
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FIGURE 7.  Akt and p70S6k resting and contracted phosphorylation.  Protein analysis of 
markers of protein synthesis signaling in aged (20-month old) mouse gastrocnemius muscle 
via Western blot after the 28-day supplementation period by treatment: control (CT), Ajuga 
turkestanica extract (ATE), and 20-hydroxyecdysone (20E).  Quantification of non-
contracted phosphorylation of AktSer473 (A) and p70S6kThr389 (B) by treatment, respectively, 
No significant differences (NSD) between groups (p < 0.05).  Quantification of contracted 
versus non-contracted (C: NC) fold change from control (CT) phosphorylation of AktSer473 
(C) and p70S6kThr389 (D) by treatment, respectively.  NSD between groups (p < 0.05). Above 
A-D are representative Western blot protein bands by treatment.   
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FIGURE 8.  Akt and p70S6k resting and contracted total protein content.  Protein analysis of 
markers of protein synthesis signaling in aged (20-month old) mouse gastrocnemius muscle 
via Western blot after the 28-day supplementation period by treatment: control (CT), Ajuga 
turkestanica extract (ATE), and 20-hydroxyecdysone (20E).  Quantification of non-
contracted total protein content of Akt (A) and p70S6k (B) by treatment, respectively.  No 
significant differences (NSD) between groups (p < 0.05).  Quantification of contracted versus 
non-contracted (C: NC) fold change from CT total protein content of Akt (C) and p70S6k 
(D) by treatment, respectively. NSD between groups (p < 0.05). Above A-D are 
representative Western blot protein bands by treatment.   
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FIGURE 9.  p38-MAPK and AMPK resting and contracted phosphorylation.  Protein 
analysis of markers of mitochondrial biogenesis signaling in aged (20-month old) mouse 
gastrocnemius muscle via Western blot after the 28-day supplementation period by 
treatment: control (CT), Ajuga turkestanica extract (ATE), and 20-hydroxyecdysone (20E).  
Quantification of non-contracted phosphorylation of p38-MAPKThr180/Tyr182 (A) and 
AMPKThr172 (B) by treatment, respectively.  No significant differences (NSD) between 
groups (p < 0.05).  Quantification of contracted versus non-contracted (C: NC) fold change 
from CT phosphorylation of p38-MAPKThr180/Tyr182 (C) and AMPKThr172 (D) by treatment, 
respectively.  *Denotes significantly different from CT and #denotes significantly different 
from ATE, respectively.  Above A-D are representative Western blot protein bands by 
treatment. 
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FIGURE 10.  p38-MAPK and AMPK resting and contracted total protein content.  Protein 
analysis of markers of mitochondrial biogenesis signaling in aged (20-month old) mouse 
gastrocnemius muscle via Western blot after the 28-day supplementation period by 
treatment: control (CT), Ajuga turkestanica extract (ATE), and 20-hydroxyecdysone (20E).  
Quantification of non-contracted total protein content of p38-MAPKThr180/Tyr182 (A) and 
AMPKThr172 (B) by treatment, respectively.  No significant differences (NSD) between 
groups (p < 0.05).  Quantification of contracted versus non-contracted (C: NC) fold change 
from CT total protein content of p38-MAPKThr180/Tyr182 (C) and AMPKThr172 (D) by treatment, 
respectively.  NSD between groups (p < 0.05). A-D are representative Western blot protein 
bands by treatment.   
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    NCRC IACUC Application 
11-008 – Shanely 
Phytoecdysteroids vs sarcopenia 
Approved:  4/8/2011 
Page 1 of 1 
 
 
 
ANIMAL RESEARCH PROTOCOL 
DATE SUBMITTED:  MARCH 17, 2011  
DATE REVIEWED:  APRIL 6, 2011 
   
For IACUC Use Only:: 
IACUC No.: 11-008 Date of Approval: 4/8/2011 
  
 
NOTE: Use a separate form for each species.  DO NOT include individual appendices if they are not relevant to the protocol being described.   
TO CHECK BOXES, double click, then select “Checked” in Default value section.   
ACRONYMS:  Define all abbreviations the first time they are used.  TABLES/ROWS:  To add a row to a table, click inside one of the existing table 
cells, then select Table, Insert, Rows from the main menu of the program.   
 
SECTION A:  APPLICATION INFORMATION 
Complete items A.1- A.8 below; then proceed to item B. 
 
CHECK ALL THAT APPLY: 
TO CHECK BOXES, double click, then select “Checked” in Default value section.   
 
  Animals Housed Outside the CLAS 
  Breeding   
  Major Survival Surgery 
  Category E studies 
 
 
  Free-ranging Wildlife 
  Hazardous Agents   
  Chemical Hazards 
  Physical Restraint 
 
 
  Exceptions to The Guide 
  Comments:   
 
 
  
1.  PRINCIPAL INVESTIGATOR:   R. Andrew Shanely, Ph.D. 
2.  DHMRI ADDRESS & 
CONTACT INFORMATION: 600 Laureate Way, Kannapolis NC 28081 
     PHONE: 704-250-5357 EMAIL: shanelyra@appstate.edu 
3.  PROPOSAL TITLE:   Naturally-produced phytoecdysteroids from Ajuga turkestanica as a countermeasure against sarcopenia  
4.  ANIMAL SPECIES COVERED BY THIS PROTOCOL:    
(Only one species per protocol) 
Mouse 
5. FUNDING SOURCE:  GRANT TITLE and/or NUMBER:  
Indicate the source(s) of funds that will be used to perform these animal procedures once approved by the IACUC: 
 Department of Veterans Affairs  U. S. Public Health Service (e.g. NIH)   
 Private or Charitable Foundation.   Identify:   
 University Departmental Funds. Identify University and Department:   
 Private Company Identify:   
 Other: Identify:  Internal (ASU) funding via research indirects 
 
A6.  Is this a new protocol for a new project? 
 Yes.  If YES, proceed to item 7. 
 No.  If NO, answer A.6.a.-d. below. 
a.   Indicate the status of this protocol below: 
 This is an unchanged, approved protocol intended for a new funding source. 
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150 Research Campus Drive • Kannapolis • North Carolina 28081 • Direct 704 250 2600 • Fax 704 250 2609 • www.ncresearchcampus.net   
 
 
Notice of Initial Protocol Approval 
 
TO: Dr. R. Andrew Shanely 
 600 Laureate Way,  NCRC 
 
FROM: Dr. Lawrence Mays 
 NCRC IACUC Chair 
 
SUBJECT: Approval of Protocol #11-008 
TITLE: “Naturally-produced phytoecdysteroids from  
 Ajuga turkestanica as a countermeasure against sarcopenia”  
 
DATE:  April 8, 2011 
 
The North Carolina Research Campus Institutional Animal Care and Use Committee (IACUC) approved the protocol 
“Naturally-produced phytoecdysteroids from Ajuga turkestanica as a countermeasure against sarcopenia” on 
April 8, 2011. 
 
Approvals are valid for one (1) year and may be renewed before the anniversary of the original approval date for a total 
of three (3) years of study.  A renewal/status report is due annually for IACUC protocols and must be submitted along 
with the renewal request form.  After three years, a new protocol application must be submitted to continue the study.  
Please note the following information: 
 
Protocol #:    11-008 
Title:   “Naturally-produced phytoecdysteroids from  
   Ajuga turkestanica as a countermeasure against sarcopenia”  
 
Renewal #1 due and approved before: April 8, 2012 
Renewal #2 due and approved before: April 8, 2013 
Expiration date:    April 8, 2014 
 
Please note that it is the investigator’s responsibility to promptly inform the committee of any proposed changes in this 
study, as well as any unanticipated problems that may occur involving care and use of animals. 
 
All changes (i.e., adding or removing personnel from this study, changing strains, changes in procedure or in prescribed 
animal care, etc.) must be submitted to the IACUC by way of an Amendment.  All amendment and renewal forms are 
available through the IACUC office. 
 
It is also the investigator’s responsibility to maintain detailed surgical records if the IACUC-approved study involves 
surgical procedures.  These records must be available to the Center for Laboratory Animal Sciences (CLAS) Director 
and the Attending Veterinarian and a copy must be kept with the animals at all times. 
 
If you need additional information or assistance, please contact Dixie Airey at 704-687-3311. 
 
Approval Authorized by: 
 
__________________________________ _________________ 
Dr. Lawrence Mays, NCRC IACUC Chair  Date 
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